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Laura M. Rank: Characterization of the Mycobacterial Mce4 transporter 
(Under the direction of Dr. Miriam Braunstein) 
The Mce transporters of mycobacteria import lipids from the environment, across an 
outer and an inner membrane (diderm structure), and into the cytoplasm where lipids serve as 
precursors for lipid biogenesis or can be broken down for energy. Each mce operon is composed 
of two predicted permease-encoding genes and six mce genes encoding proteins (MceA-F) 
predicted to function as solute binding proteins (SBPs). Genes encoding Mce Associated 
Membrane (Mam) proteins are linked to mce operons, although their function remains unknown. 
Furthermore, there are orphaned Mce Associated Membrane proteins (Omams), which share 
predicted structural similarity to Mam proteins but are encoded by genes that are not linked 
to mce operons. An unlinked gene encodes an ATPase, MceG, that is predicted to function in all 
Mce systems. Our goal is to determine how Mce transporters work by characterizing the Mce4 
transporter, a cholesterol import system for mycobacteria. To define contributions of Mce 
proteins, we began by making mutants lacking individual Mce4 proteins in the model 
mycobacteria, M. smegmatis, and analyzed Mce4 transporter function of the mutants using 
cholesterol uptake and utilization assays. Our results demonstrate that Mce4A,E,F, Mam4A,B, 
and OmamA,B proteins each have non-redundant roles. We hypothesized that Mce4A,E,F, 
Mam4A,B, and OmamA,B function together in a large, multi-protein complex. In support of our 
hypothesis, we discovered that the absence of individual Mce, Mam or Omam proteins results in 
reduced levels of the other Mce4 components, which is consistent with these proteins stabilizing 





immunoprecipitations (IPs) identified all mce locus-encoding components (YrbE4A,B, Mce4A-
F, Mam4AB) as well as OmamA,B, and MceG as interactors of Mce4A-HA, suggesting that 
these components exist in complex with one another. The IP-MS analysis also reveals potentially 
unidentified components of the Mce4 transporter. Our characterization of the Mce4 transport 
system provides evidence of a multi-protein complex with non-redundant components in the 
mycobacterial cell wall and lays the ground work to address mechanistic questions of cell 
envelope lipid transport, answers to which will provide insight into the challenges of lipid 
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CHAPTER 1: INTRODUCTION 
Mycobacterium tuberculosis (Mtb) is the causative agent of the disease tuberculosis (TB). 
In 2019, 1.4 million people died from TB and 10 million people fell ill with disease. Prior to 
2020 and the outbreak of Covid-19, whose toll has yet to be determined, Mtb was the world’s 
leading infectious killer (1).  
Current treatment of non-resistant Mtb consists of the administration of four front-line 
drugs (rifampin, isoniazid, ethambutol, and pyrazinamide) for 6-9months. The success rate for 
standard TB treatment is 85% (1). Failed TB treatment and lack of compliance has resulted in 
Mtb drug resistant strains. Multidrug resistant (MDR) Mtb stains are strains that are resistant to at 
least two front-line TB drugs, isoniazid and rifampin. Until 2019, MDR-TB treatment consisted 
of up to 20 months of a toxic drug regimen that has a treatment success rate of 57% (1). Beyond 
the terrible side effects of this MDR-treatment, which include hearing loss and psychosis, this 
cocktail of drugs includes daily injectables and IV infusion treatments, which necessitate the 
need for in-office administration, leading to further lack of treatment compliance and continued 
transmission of drug-resistant Mtb (TB Alliance, website). Excitingly, in 2019 the FDA 
approved another treatment regime, BPaL, as a therapeutic for highly treatment-resistant 
tuberculosis. The BPaL regime consists of three drugs, bedaquiline, pretomanid, and linezolid for 
6-9 months, which is a dramatic improvement to the standard, 20-month MDR treatment regime. 
In addition to MDR-TB, there are also Mtb strains that are classified as extensively drug resistant 




additionally resistant to fluoroquinolones and at least one other second-line injectable drug. 
XDR-TB cases have been reported on all continents (2). As the name suggests, there are no 
current treatment options for TDR infections (3).  
Globally, TB is a devastating health and economic burden (1), and the impact of TB 
disease is reflected in the World Health Organization (WHO) End TB Strategy. The End TB 
Strategy calls for a 50% reduction in the TB incidence rate and a 75% reduction of TB deaths by 
2025, as compared to 2015 data (WHO END TB strategy website). So far, from 2015 to 2019, 
there has been a 9% reduction rate in TB incidence and 14% reduction of TB deaths (1). To 
further reduce TB cases and casualties and meet the End TB goals, new drugs are needed to treat 
TB.  In accordance, the United Nations has called for an increase of funding to be provided for 
TB prevention, diagnosis, and treatment as well as for TB research. Currently, there are 22 TB 
drugs enrolled in Phase I, II, or III clinical trials, 13 of which are new compounds (1). 
Additionally, the introduction of BPaL and its shortened treatment regimen is a welcome change 
to previous treatment of resistant-Mtb. However, there is still a dire need for new drugs to treat 
resistant mycobacteria, especially when considering that MDR-TB cases increased by 10% from 
2018 to 2019 with 0.5 million cases reported that year (1).  
Beyond the devastating, direct effects of Covid-19, Covid-19 will also impact the 
ongoing efforts to quell TB. Covid-19 will stall, if not prevent the achievement of the WHO End 
TB Strategy goals, as Covid-19 outbreaks are delaying diagnosis and treatment of TB. For 
example, in India, Indonesia, and the Philippines detection and treatment of TB fell by 25-30% 
as compared to the same 6-month period in 2019 (January-June 2020) (1, 4). Considering Covid-




could increase by 0.4 million in 2020 alone and that the number of people who contract TB could 
increase by over 1 million per year between 2020 and 2025 (1, 4, 5).  
To address the desperate need for new treatments to control TB, there is increased 
interest in discovery and development of new anti-TB drugs. Identification of novel drug targets 
marks the beginning of the drug discovery pipeline. Mtb, and mycobacteria in general, can be 
defined by their relationship with lipids, which are important to mycobacterial physiology and 
virulence, and can be essential for mycobacterial growth and viability. Understanding Mtb and 
its relationship with lipids could lead to the discovery of novel, TB-specific drug targets.  
Lipids characterize the lifestyle of mycobacteria 
Mycobacteria are characterized by the unique abundance and repertoire of lipids in their 
cell envelope (6). Using a Gram stain procedure, most bacteria can be classified as Gram-
positive or Gram-negative, which correlates with how much peptidoglycan is present in the 
bacterial cell envelope. Canonical Gram-positive bacteria have a cell envelope defined by a 
cytoplasmic lipid bilayer membrane surrounded by a thick cell layer of peptidoglycan (Figure 
1.1B). During the Gram stain, heat fixed bacteria are treated with crystal-violet dye, which a 
thick layer of peptidoglycan (i.e., a Gram-positive bacterium) will retain. Canonical Gram-
negative bacteria have a cell envelope defined by a cytoplasmic (inner) lipid bilayer membrane 
(IM), a thin layer of peptidoglycan that exists within a gel-like periplasmic space, and an outer 
lipid bilayer membrane (OM) (Figure 1.1A). The thin layer of peptidoglycan of Gram-negative 
bacteria does not retain the crystal-violet stain of the Gram stain procedure and so the dye is 
washed away in subsequent steps (7). Mycobacteria do not reliably stain Gram-positive or Gram-
negative because Gram stain dyes cannot penetrate the lipids present in the mycobacterial cell 




officially classifies mycobacteria as GC (guanidine and cytosine nucleotides)-rich Gram-positive 
bacteria, belonging to the Phylum Actinobacteria (9). While genomically classified as Gram-
positive, the mycobacterial cell envelope structure more closely resembles that of a Gram-
negative bacterium (10–12). 
Lipids contribute to mycobacterial cell envelope structure 
The mycobacterial cell envelope (Figure 1.1C) contains a cytoplasmic (inner) lipid 
bilayer membrane (IM), surrounded by a layer of peptidoglycan covalently linked to another 
carbohydrate polymer of arabinose and galactose, arabinogalactan, that is esterified to mycolic 
acids. This unique covalent network of peptidoglycan, arabinogalactan, and mycolic acids is 
referred to as the mAGP complex and is considered the core of the mycobacterial cell wall (13).  
A bilayer of lipids, constituted by mycolic acids and extractable, free lipids, forms the 
mycobacterial outer membrane (MOM) (6, 13, 14). 
Mycolic acids are unusually long chain fatty acids (C60-C90) and they represent the 
majority of the lipid content of the mycobacterial cell envelope (15). Mycolic acids are essential 
to mycobacteria, as deletion of genes encoding proteins required for mycolic acid synthesis or 
transport  is lethal (16, 17). Mycolic acids are synthesized within the mycobacterial cytoplasm as 
trehalose monomycolates (TMM). After TMM is flipped across the IM, TMM can be esterified 
to arabinogalactan, forming the mAGP complex, or can serve as a mycolic acid donor to create 
trehalose dimycolates (TDM), which exists freely in the MOM (14, 16). Mycolic acids are 
central to the mycobacterial cell envelope structure as they not only connect to the carbohydrate 
layer of peptidoglycan and arabinogalactan, but also form the inner leaflet of the (MOM) (6, 13, 
14). Various other complex lipids and glycol-lipids that are non-covalently linked to mycolic 




phosphatidylinositol mannosides (PIMs), the phthiocerol dimycocerosates (PDIMs), sulfolipids 
(SL), acyltrehaloses, and (mannose-capped-) lipoarabinomannan (ManLAM or LAM) (6). While 
the presence of a MOM has been speculated for some time, it was not until 2008 that cryo-
electron microscopy studies confirmed the presence of a MOM (18, 19). The plethora of unique 
cell envelope lipids mycobacteria possess contributes to the impervious nature of the 
mycobacterial cell envelope, which is best exemplified by  the inherent drug resistance of 
mycobacterial pathogens, including Mtb (20).  
The course of TB disease 
Mtb is spread from person to person via aerosol droplets. Transfer of as few as 3-5 Mtb 
cells is sufficient to initiate infection (21). Inhaled Mtb enter the alveoli of the lungs and are 
taken up by phagocytic cells, such as macrophages, wherein the bacteria replicate. Following 
Mtb replication inside the macrophage, infected macrophages will later undergo necrosis, which 
releases the intracellular Mtb to go on and infect new macrophages. This cycle of replication and 
reinfection results in exponential growth (active growth). Infected macrophages also produce 
cytokines to attract more immune cells to the infection site and infected macrophages migrate 
through the lymphatic system and the host will mount a cell-mediated TH1 immune response. 
Antigen specific CD4+ and CD8+ T cells then migrate towards and wall off the infection, but not 
necessarily sterilize infection, to form a granuloma (22, 23).  
Granulomas are complex, dynamic structures. Mature granulomas contain a caseous 
necrotic center made up of debris from phagocytic cells that once harbored Mtb. The 
granuloma’s caseum is surrounded by a layer of macrophages that include macrophages that 
have differentiated into multi-nucleate, foamy, or epithelioid macrophages (24–27). Multi-




lipid inclusions; the purposes of multi-nucleate and foamy macrophages towards controlling 
infection remains unclear. Epithelioid macrophages have highly interdigitated cell membranes 
that create strong links with adjacent cells, barricading the infection (26, 27). This layer of 
macrophages is further surrounded by other cell types that include B and T cells, natural killer 
(NK) cells, and fibroblasts, which secrete an extracellular matrix (25, 28). Mtb can persist 
extracellularly in the necrotic center of granulomas or intracellularly in macrophages that 
surround the core of the granuloma.  
In the granuloma, Mtb are held within a low oxygen (hypoxic) and nutrient-limited 
environment. These features of the granuloma can drive Mtb into a nonreplicating persistent state 
(28) associated with latent infection (90% of TB cases) (22). Latent Mtb infection is controlled 
by the granulomatous immune response. However, if the balance between Mtb and the immune 
system is compromised, latent Mtb in granulomas can reactivate to cause disease (22). During 
reactivation, the Mtb bacteria resume active growth and tissue necrosis leads to lung damage, 
irritation, and coughing that will transmit Mtb to a new host. If active infections are allowed to 
progress, pulmonary insufficiency can lead to death (21).  
Lipids influence TB disease progression 
In addition to being structural components of the mycobacterial cell envelope, lipids 
interface with the host during infection and influence early disease progression by helping Mtb 
evade the host immune system. A few well-studied examples of MOM/surface-exposed lipids 
crucial to Mtb virulence include PDIMs, ManLAM, SLs, and PGLs (14, 29). These lipids enable 
Mtb to evade immune clearance, particularly detection by the innate immune system at early 
stages of infection, by masking detection of Mtb by host immune cells, promoting uptake by 




dampening the production of proinflammatory cytokines (30). For example, PDIM is a methyl-
branched fatty acid-containing surface glycolipid. It has been shown that PDIM-deficient Mtb is 
attenuated in a guinea pig model of infection (31, 32), and transposon mutagenesis studies show 
that transposon insertions in PDIM synthesis genes result in attenuation in mouse models of 
infections (33, 34). PDIM contributes to Mtb evasion of the immune system by physically 
masking pathogen-associated molecular patterns (PAMPS) (35). PAMPS are conserved motifs 
found on pathogen associated molecules that stimulate toll-like receptors (TLRs) of host innate 
immune cells. Once activated, TLRs trigger NF-кβ signaling pathways that turns on pro-
inflammatory cytokine production (30, 36). The mycobacterial cell envelope, with its many 
unique lipids, is replete with PAMPS. However, PDIM physically masks mycobacterial cell 
envelope PAMPS, reducing recognition by TLRs, and thereby preventing the recruitment of 
iNOS+ microbicidal macrophages (35). Studies of transposon mutants unable to produce another 
mycobacterial cell envelope lipid, SL, also indicate that SLs  dampen the host innate immune 
response by suppressing TLR2 signaling (36). The cell envelope lipid ManLAM also acts to 
decrease pro-inflammatory cytokine production via NF-кβ signaling. However, instead of 
blocking TLRs like PDIM and SL, ManLAM binds the C-type lectin DC-SIGN receptor that 
reorients NF-кβ to transcribe genes that encode for anti-inflammatory cytokines (37). The Mtb 
cell envelope lipid, PGL, stimulates host chemokine receptor 2 (CCR2) to recruit permissive 
macrophages to the site of infection, providing a niche for Mtb to grow exponentially (35). 
PDIM, ManLAM, SL, and PGL provide a few examples of how the mycobacterial cell envelope 
lipids promote immune evasion; however, these and many other lipids can play additional roles 




The importance of lipids as a nutrient source for mycobacteria during infection was first 
suggested in 1965, when Segal and Bloch reported that fatty acids induce ex vivo respiration of 
Mtb cultured from mouse lung tissue and that carbohydrates could not induce respiration (38). 
Since those early studies, it is well established that mycobacteria utilize both host fatty acids and 
cholesterol for survival and growth during infection as exemplified by the attenuated infections 
of lipid metabolism Mtb mutants in mice (39–44). Additionally, genes involved in fatty acid or 
cholesterol utilization are upregulated during Mtb infection of macrophages (45–47).  
It is also noteworthy that, during infection, Mtb exists within environments that contain 
lipids. Macrophages infected with mycobacteria can accumulate lipid bodies of triglycerides 
(TAG) and cholesteryl esters (CE), creating foamy macrophages. Mycobacteria will export 
lipolytic enzymes to degrade these foamy macrophage lipid bodies, import the lipids, and create 
their own intra-cytosolic lipid inclusions that have been hypothesized to be metabolized during 
latency (48, 49). Additionally, cholesterol accumulates within the caseous center of human 
tuberculosis granulomas (24). There is also precedent for Mtb assimilation of host lipids, as Mtb 
has been shown to associate with and assimilate exogenous, fluorescently labeled lipids during 
macrophage infection (50–53). Lipids can then be metabolized by Mtb to produce energy and 
serve as precursors for the synthesis of other lipids, including cell wall lipids, that are important 
for Mtb physiology and virulence (54, 55).  
Transport of lipids between inner (IM) and outer (OM) membranes in diderm bacteria 
For all the important functions that mycobacterial and host lipids play in cell envelope 
architecture, virulence, and mycobacterial metabolism, lipids need to move through the 
mycobacterial cell envelope, traveling between two hydrophobic lipid membranes (IM and OM) 




hydrophobic lipids are not soluble in a hydrophilic periplasm, and (2) the periplasm is devoid of 
an energy source. Extremely little is known about how lipids travel between membranes in 
mycobacteria (12). While still not completely understood, this question has been studied in 
Gram-negative bacteria, most notably in the model organism, Escherichia coli (56–58). As both 
Gram-negative bacteria and mycobacteria possess an IM and OM, the lipid transport systems of 
E. coli might provide insight or parallels to lipid transport in mycobacteria.  
Transport of lipids across the cell envelope of E. coli, a Gram-negative bacterium  
The OM of E. coli contains three major types of lipids: lipopolysaccharide (LPS), which 
makes up the outer leaflet of the OM, phospholipids, which make up the inner leaflet of the OM, 
and lipoproteins, which are proteins that contain a lipid moiety to anchor them within either the 
IM or OM of E. coli. Transport systems for all three of these outer membrane lipids have been 
identified and are discussed below.  
LPS is composed of three different moieties including lipid A, a core oligosaccharide, 
and the O-antigen polysaccharide. Lipid A and part of the core oligosaccharide are synthesized 
in the cytoplasm by nine enzymes that make up the conserved Raetz pathway (59). 
Glycosyltransferases then attach the remaining core oligosaccharide residues, and this molecule 
is flipped across the IM by an ABC transporter, MspA. The O-antigen is made separately in the 
cytoplasm and also flipped across the IM by another ABC transporter, Wzx (60).  Classical ABC 
transporters are transport systems that use the power of ATP to transport substrates across the 
IM. The minimum unit for an ABC transporter includes a permease, an integral membrane 
protein through which substrates cross the membrane, and a cytoplasmic ATPase, which 
hydrolyzes ATP to provide energy for translocation (61).  Once fully assembled on the 




lipopolysaccharide transport (Lpt) machinery (60, 62). The Lpt transporter is also an ABC 
transporter, but more complex; rather than transporting substrates across the IM, Lpt transports 
lipids from the IM, across the periplasm, and into the OM. The Lpt system, composed of seven 
proteins, LptA-G, creates a bridge of proteins that connects the inner and outer membrane of E. 
coli (Figure 1.2A). LptFG permease subunits and the ATPase, LptB, work together to extract 
LPS from the outer leaflet of the IM and transfer the LPS to the IM localized lipoprotein, LptC. 
LptC passes LPS to LptA, a periplasmic protein that multimerizes to form a bridge of LptA 
proteins that spans the periplasm, connecting the IM LptBFGC complex to the OM. At the OM, 
LptA interacts with the LptDE complex. LptD is an OM beta barrel protein, and LptE is a 
lipoprotein. Successive rounds of ATP hydrolysis powers the IM, LptBFG ABC transporter unit 
to repeatedly extract LPS from the IM. Each extracted molecule of LPS subsequently pushes the 
previously extracted LPS up into and through the LptA bridge in a PEZ-like model of movement 
until it reaches the OM LptDE complex (60, 62) (Figure 1.2A).  The LptDE complex functions 
to insert LPS into the outer leaflet of the outer membrane, but the mechanism of this insertion 
remains unclear. 
Lipoproteins are synthesized in the cytoplasm with a N-terminal signal peptide that 
contains a lipobox motif (Leu-3-(Ala/Ser)-2-(Gly/Ala)-1-Cys+1). Lipoproteins are exported across 
the IM by the Sec pathway. After export, the conserved Cysteine at the +1 position of the 
lipobox is the target of lipid acylation by Lgt. LspA then cleaves the signal peptide, and the +1 
Cysteine becomes the N-terminal amino acid of the lipoprotein. Next, Lnt adds another acyl-
chain to the +1 Cysteine. Thus, after processing by Lgt, LpsA, and Lnt, the lipoprotein will lack 
a signal peptide and be triacylated, anchoring the lipoprotein within the IM (63–65). However, 




aspartate residue at the +2 position of the mature protein, the residue after the +1 Cysteine of the 
lipobox, are predicted to remain localized to the IM, following the “+2 rule”. Lipoproteins 
lacking an aspartate at the +2 position traffic further to the OM (66). Lipoproteins in the OM 
travel across the periplasm, via the localization of lipoproteins (Lol) pathway (64). In E. coli, the 
Lol pathway consists of five proteins, LolABCDE. LolCDE compose an ABC transporter using 
the energy from ATP hydrolysis (LolD) to release lipoproteins from the IM and pass them from 
the permease subunits, LolCE, to LolA. LolA serves as a chaperone protein for lipoproteins, 
shielding the lipid tails and shuttling them across the aqueous periplasm. LolA then passes the 
carried lipoprotein to LolB, itself an OM lipoprotein, that inserts the carried lipoprotein into the 
OM (64) (Figure 1.2B).  
Phospholipids are made within the cytoplasm and self-populate the inner and outer leaflet 
of the IM of Gram-negative bacteria (67–69). Phospholipids are also present on the inner leaflet 
of the OM. How phospholipids traverse the periplasm to reach the OM is the least understood 
process of lipid cell envelope biogenesis in E. coli (57, 58). Recently, the Maintenance in lipid 
asymmetry (Mla) transporter has been identified as playing a role in transporting phospholipids 
between the IM and OM (70). However, it remains unclear and controversial, if the Mla system 
supports retro and/or anterograde transport of phospholipids between the membranes (71–73). 
Similar to the Lpt and Lol transport systems, the Mla system also involves an ABC transporter 
(Figure 1.2C). The core ABC transporter unit consists of the ATPase, MlaE, and the permease 
MlaF. MlaEF is stabilized at the inner membrane by the cytoplasmic, STAS domain-containing 
protein, MlaB (74, 75). MlaD, acts as a solute binding protein (76). Solute binding proteins 
(SBPs) are periplasmic proteins that deliver solutes to ABC transporter permeases. MlaD 




periplasmic MCE domain. MCE domains are found exclusively in proteins located in diderm 
bacteria and eukaryotic chloroplasts (77), and they are increasingly associated with lipid binding 
(76, 78). MlaD forms a homo-hexamer at the IM that creates a pore-like structure through which 
phospholipids can translocate to or from the other Mla ABC transporter components (76, 79). 
Interacting with the IM MlaBDEF complex is a periplasmic chaperone protein, MlaC. MlaC 
additionally interacts with an OM MlaA/OmpCF complex, presumably ferrying phospholipids 
between the IM and OM (72, 80). The OM MlaA/OmpCF complex is thought to either extract or 
insert phospholipids in the OM, but this has yet to be determined (80).  
In addition to the Mla system, E. coli has two other MCE-domain containing proteins, 
YebT/LetB and PqiB, that have been shown to bind phospholipids (78, 81, 82). Interestingly, 
unlike MlaD, YebT/LetB and PqiB contain multiple MCE domains. YebT/LetB possesses seven 
MCE domains and PqiB has three MCE domains. Cryo-EM studies and crystal structures reveal 
that the YebT/LetB and PqiB proteins homo-hexamerize with the MCE domains stacking on top 
of one another. The stacked MCE domains of YebT/LetB and PqiB create a tunnel that is 
hypothesized to transport phospholipids. The cryo-EM structures of YebT/LetB suggest that the 
seven stacked MCE domains of YebT/LetB create a tunnel that is theoretically long enough to 
bridge the IM and OM. However, the three stacked MCE-domains of PqiB would not be able to 
form a tunnel that would span between the IM and OM, although it has been proposed that the 
alpha helical region proceeding the MCE-domain could connect to the OM. Other proteins and 
their functions that work with YebT/LetB and PqiB have yet to be identified (78, 81) (Figure 
1.3).  
It is noteworthy that each of the lipid transporter systems described above include an 




coli. Lipids are thereby protected while travelling between the IM and OM by the network of 
proteins these systems contain. 
Transport of lipids across the mycobacterial cell envelope  
Very little is known about how lipids travel to the outer layers of the mycobacterial cell 
envelope. Mycobacteria do not have LPS and, therefore, lack Lpt machinery homologs. While 
mycobacteria do possess lipoproteins, it is unclear whether any mycobacterial lipoproteins cross 
the cell envelope and localize to the MOM. It is possible that all mycobacterial lipoproteins are 
anchored to the IM, but with over 100 lipoproteins encoded within the Mtb genome, it seems 
unlikely that all 100 lipoproteins would be IM localized (12). However, mycobacteria lack direct 
homologs to the Lol transport system, so it remains unclear how lipoproteins traffic to the MOM, 
or even if OM trafficking of lipoproteins  occurs. Mycobacteria also lack a homologous Mla 
transporter, but mycobacteria do contain MCE domain-containing proteins and these proteins are 
a focus of this thesis. The roles of mycobacterial Mce proteins are further discussed below (77). 
Transport of lipids across the mycobacterial IM to the cell wall 
Currently, the best understood aspect of mycobacterial lipid transport is how some of the 
novel mycobacterial lipids are transported from their site of synthesis in the cytoplasm across the 
IM (12). Many cell wall lipids travel across the IM using mycobacterial membrane protein large 
(MmpL) proteins (83, 84). MmpL proteins are members of the resistance, nodulation, and cell 
division (RND) protein superfamily. RND proteins are large integral membrane proteins (>100 
kDa) that typically contain 10-12 transmembrane domain (TMD) segments. RND proteins often 
form homo- or heterotrimers. In E. coli and other Gram-negative bacteria, RND proteins act as 
efflux pumps, contributing to antibiotic resistance and stress responses. Gram-negative RND 




(OMFs) at the OM to form tripartite (RND-MFP-OMF) efflux systems that connect both 
membranes (85). In contrast to the RND efflux pumps of E. coli that can transport substances 
across the periplasm and out of the cell, the MmpL proteins of mycobacteria have not been 
shown to form transport systems that connect the IM to the OM. To date, no MFP homologs that 
work with mycobacterial MmpL proteins have been identified, despite speculation that 
mycobacterial membrane protein small (MmpS) proteins or lipoproteins could potentially serve 
as cognate MFPs (83). At the current time, the only role assigned to mycobacterial MmpL 
proteins is that of transporting substrates, most commonly lipids, from the cytoplasm across the 
IM (83). Different species of mycobacteria have different numbers of MmpL proteins. 
Mycobacterium leprae, which is the mycobacterium species with the most reduced genome, 
maintains five MmpL proteins, whereas Mycobacterium absessus has 31 MmpL proteins. In 
Mtb, there are 13 MmpL proteins, five of which have defined lipid substrates and two of which 
function in transporting siderophores (83).  
In addition to the common association of mmpL genes with genes required for lipid 
biosynthesis, accumulating evidence from characterization of multiple mmpL mutants (mmpL3, 
7, 8, 10, 11) demonstrates that MmpL proteins are involved in lipid transport to the cell 
envelope. MmpL4 and MmpL5 transport mycobacterial siderophores across the IM, and the 
substrates of the remaining Mtb MmpL proteins (MmpL1, 2, 6, 9, 12, and 13) have not been 
conclusively identified (12, 83). MmpL3 flips the acylated sugar precursor of mycolic acids, 
TMM, across the IM where it can be used in the assembly of the mycobacterial cell envelope. 
Native mass spectrometry demonstrates that MmpL3 can bind a variety of lipids, including 
TMM and phosphatidylethanolamine (PE) (86). MmpL3 is the only essential MmpL of Mtb 




Mtb inhibitor campaigns (87, 88). Most notably, the MmpL3 inhibitor SQ109, for which a phase 
II/III clinical trial in the Russian Federation was completed in 2017, and showed positive results 
in efficacy when added to the standard treatment regimen for MDR-TB. A Phase II trial is 
currently being planned for the USA (1, 89, 90). MmpL7 transports PDIM across the IM of Mtb; 
interestingly, PDIM translocation also requires the Drr ABC transporter (33). MmpL8 transports 
SLs (91) and MmpL10 transports diacyltrehaloses (DAT) (92) across the IM of Mtb. MmpL11 
transports long-chain triacylglycerols and mycolate wax esters across the IM of Mtb, and these 
lipids play important roles during biofilm formation (93). Mtb mmpL11 mutants are also 
attenuated for persistent infection in mice, suggesting that the lipid substrates of MmpL11 are 
important for long term Mtb persistent infection (93, 94).  
Transport of lipids beyond the mycobacterial IM 
How mycobacterial lipids traffic beyond the IM remains unknown. However, several 
lipoproteins belonging to the Llp (lipid binding lipoprotein) family have been implicated in 
transporting lipids beyond the IM of mycobacteria (95–97). LppX, LpqN, and LprG are 
examples of lipoproteins whose proposed function is to transport lipids beyond the mycobacterial 
IM.  
PDIM is transported across the IM by MmpL7 (33), and it is suggested that the 
lipoprotein LppX subsequently transports PDIM to the MOM (95). Transport of PDIM to the 
MOM by LppX is supported by the absence of PDIM in the culture filtrates of Mtb ΔlppX mutant 
strains. When grown in liquid cultures supplemented with the detergent Tween, WT Mtb strains 
will shed PDIM into the culture filtrate. Therefore, the lack of PDIM in culture filtrates of the 
Mtb ΔlppX mutant suggests that PDIM is no longer localized to the outer layers of the MOM. 




support of LppX functioning to transport PDIM comes from the genomic location of lppX. The 
lppX gene is clustered with mmpL7 and genes required for PDIM synthesis. Notably, lppX 
orthologs are absent from non-pathogenic mycobacteria, such as M. smegmatis, that also lack 
PDIM (95). While so far, no protein-protein interaction studies can connect LppX and MmpL7, 
LppX presumably functions downstream of MmpL7 to transport PDIM to the MOM.  
There is evidence that the lipoprotein LpqN may function with MmpL3 and MmpL11 to 
transport mycolic acid-containing lipids beyond the IM. MmpL3 transports TMM across the IM 
of mycobacteria and is the only essential MmpL for mycobacteria (86). MmpL11 transports 
mycolic acid-containing lipids, such as mycolate wax esters and monomeromycolyl 
diacylglycerol; the presence of these lipids is reduced from the mycobacterial surface in a 
ΔmmpL11 mutant compared to WT mycobacteria growing in biofilms (98). The genes encoding 
MmpL3 and MmpL11 are clustered together in the genome and MmpL3 and MmpL11 interact 
with one another in protein-protein interaction studies (92), suggesting that MmpL3 and 
MmpL11 functions are coordinated. Similarly, protein interactions studies also reveal that LpqN 
binds to the periplasmic loops of MmpL3 and MmpL11 and interacts with the antigen 85 (Ag85) 
complex (96). The Ag85 complex transfers mycolic acids from TMM to form TDM and transfers 
mycolic acids from TMM to mAGP (99, 100). The LpqN, MmpL3/11, and Ag85 interactome 
suggests that LpqN may receive lipid from MmpL3/11 and transport mycolic acid-containing 
lipids for modification (at Ag85) or to the deeper layers of the cell envelope (96). This 
hypothesis is supported by the ability of LpqN to bind dodecyl-trehalose, a substrate similar to 
TMM. However, lipid profiles of a ΔlpqN mutant have not been shown to be altered from WT 





Another lipoprotein that has been shown to interact with and potentially transport lipids 
within the cell envelope is LprG. A ΔlprG mutant has a surface display defect of LAM and has 
an intracellular accumulation of triacylglycerides when compared to WT bacteria (97, 101, 102). 
Additionally, in a vesicle based in vitro assay, LprG transfers triacylglyceride between bilayer 
membranes (102). LprG binds triacyl lipids in vitro and crystal structures show LprG in complex 
with LAM core lipid (103). Taken together, these data shows that LprG transports LAM and 
triacylglycerides throughout the cell envelope. However, in contrast to LppX or LpqN, LprG and 
its lipid substrates are not associated with MmpLs; therefore, the mechanism of LprG lipid 
transfer may be unique.  
Overall, there is strong evidence that supports the function of some lipoproteins in lipid 
transport throughout the mycobacterial cell envelope; however, the mechanism of how 
lipoproteins contribute to lipid transport this in unknown. In Gram-negative bacteria, lipoproteins 
can be attached to either the IM or the OM; however, there is much to be learned about where 
mycobacterial lipoproteins localize (i.e., to the IM or MOM). If mycobacterial lipoproteins are 
restricted to the IM, the aforementioned lipoproteins involved in lipid transport must work in 
conjuncture with other proteins to transport lipids further into the mycobacterial cell envelope. 
Thus, much is left to be learned about lipid transfer to the outer layers of the mycobacterial cell 
envelope.  
Import of lipids through the mycobacterial cell wall: Mce transporters  
Mycobacterial Mce transporters act as lipid importers (44, 104–107). The number of Mce 
transporters mycobacteria possess varies among different mycobacterial species. Mycobacterium 
smegmatis encodes six Mce transporters (Mce1, 3, 4, 5a, 5b, 7), M. leprae encodes only one Mce 




various Mtb Mce transporter mutants for growth on and uptake of lipids show that Mce1 imports 
the fatty acids palmitic and oleic acid, and Mce4 imports cholesterol (44, 104–107). The 
substrates of other Mce transporters remain unknown, but are also suspected to be lipids.  
Although now primarily thought of as lipid importers, mycobacterial Mce proteins were 
first identified in 1993 when a fragment of Mtb Mce1A, which was heterologously produced in 
E. coli, was observed to promote uptake of E. coli by mammalian cells, garnering the name 
mammalian cell entry (Mce) (108). Subsequently, latex beads coated with Mtb Mce1A were 
shown to enter non-phagocytic mammalian (Hela) cells (109). Succeeding studies implicated 
other Mce proteins in facilitating uptake by host cells. Zhang et al (2017) showed that latex 
beads coated with Mtb Mce3C and overproduction of Mtb Mce3C in Mycobacterium bovis 
bacillus Calmette-Guerin (BCG) facilitates entry into macrophages (110). Mce3C and seven of 
the other 24 Mtb Mce proteins (not including Mce1A) contain an RGD motif. The Mce3C RGD 
motif binds to β2 integrin (CD18) as shown by protein-protein interaction studies, leading to 
SFKs-Syk-Vav-Rho-ROCK signal transduction and local actin rearrangement to promote uptake 
of BCG-overexpressing Mtb Mce3C into macrophages. Mutation of the Mce3C RGD motif 
blocks BCG-β2 integrin binding and uptake of BCG into macrophages (110). The Gram-negative 
bacterium Leptospira interrogans also possesses an MCE-domain-containing protein with an 
RDG motif that contributes to Leptospira cell invasion (111). Independent of the RGD motif, 
other MCE-domain containing proteins, such as MAM7 of Vibrio parahaemolyticus, promote 
attachment to host cells (112). Mycobacterial Mce proteins have also been shown to induce host 
cell signaling and cytokine pathways. For example, mutant analysis of BCG Δmce2E and 
overexpression of Mtb Mce3E in BCG experiments show that Mce2E and Mce3E prevent 




blocks ERK1/2 nuclear translocation and leads to the suppression of TNF and IL-6 cytokine 
expression (113, 114).  
All four Mce transporters have been implicated in Mtb virulence using mouse models of 
infection (44, 115–120). During murine infection, there is an initial growth phase, where Mtb 
replicates exponentially inside macrophages, followed by a persistence phase, when the Th1 cell 
mediated immune response is established and the bacterial burden persists without further 
increase in colony forming units (CFU) (121). Murine infections with mce1, 2, 3, and 4 Mtb 
mutants have led to attenuated infections, highlighting their importance to virulence. However, 
there are discrepancies in that mice infected with Δmce1Mtb mutants have resulted in both 
hypervirulent and attenuated phenotypes compared to the parental, wildtype (WT) strains of Mtb 
(115-118).  
In at least three studies, infection with Mtb Δmce1 mutants resulted in increased virulence 
of murine models of infection, as demonstrated by shorter times of survival and increased 
bacterial burden (115-117). However, there is an equal number of studies showing that infection 
with Mtb Δmce1 mutants results in attenuated infection. Studies showing a hypervirulent 
infection with Mtb Δmce1 mutants include infections of BALB/c mice via tail vein (systemically) 
(115) and infections of C57BL/6 mice via aerosol (116), in which Mtb Δmce1 infected mice 
succumbed earlier to infection than mice infected with WT Mtb. Additionally, BALB/c mice 
infected intraperitoneally with Δmce1 mutant showed increased CFU burden in the lung 
compared to WT Mtb at 15- and 30-days post infection (117). By contrast, and in support of 
attenuated phenotypes of Mtb Δmce1 infection, BALB/c mice infected intratracheally with a 
Δmce1 mutant survived longer and the bacterial burden in the lung was significantly decreased 




identified mutations in the mce1 locus as being associated with in vivo growth defects after one- 
and two-weeks post infection compared to WT Mtb (118). While the different results from these 
experiments have yet to be resolved, because of the established importance of lipid metabolism 
in Mtb pathogenesis, we believe that infection with Mtb Δmce1 strains will result in attenuated 
infection (54, 55).  
In comparison to the disparate results of testing the Mtb mce1 mutant infections in mouse 
models, infection studies of Mtb mce4 mutants consistently showed attenuated phenotypes in 
mice compared to WT Mtb infection. For example, C57BL/6 mice infected via aerosol with 
Δmce4 Mtb mutants survive longer than those infected with WT Mtb (120). When C57BL/6 mice 
were infected via tail vein injection with a 1:1 mixture of WT Mtb and Δmce4 bacteria, the 
Δmce4 bacteria show reduced bacterial burden in the lungs during the persistence phase of 
infection in comparison to WT Mtb (44). Similarly, Joshi et al. (2006) showed in a separate 
competitive infection (1:1 mixture of WT Mtb and Δmce4 bacteria) of C57BL/6 mice, that 
mutations in the mce4 locus resulted in a growth defect compared to WT Mtb, which was not 
detectable until 2-4 weeks following infection (122). In that same study, Joshi et al. (2006) 
showed that after tail vein infection of C57BL/6 mice with a 1:1 mixture of WT Mtb and Δmce1 
bacteria, the Δmce1 mutant had a growth defect after 1 week of infection (122). These bacterial 
burden data led to the hypothesis that Mce1 transporters are important to Mtb pathogenesis 
during the early stages of infection and that Mce4 transporters are important to Mtb pathogenesis 
during later stages of infection. 
Murine infection with Δmce2 or Δmce3 Mtb mutants also typically results in attenuated 
TB disease, as shown by increased survival time and decreased bacterial burden of mice infected 




exception of one study where Mtb Δmce3 mutant strains grew comparably to WT in mice (113). 
Overall, we believe that murine infection models support the importance of Mce transporters to 
Mtb virulence and disease pathogenesis.   
The mechanism of Mce transport is unknown 
In light of current data demonstrating that Mce transporters, lipid import, and lipid 
utilization is important to Mtb pathogenesis, Mce transporters have the potential to be targets for 
future anti-virulence Mtb drugs. However, rational design of lipid transport inhibitors will 
require a thorough understanding of the mechanism of lipid import by Mce systems. Clues to 
how Mce transporters function to transport lipids first came from mce operon organization. Each 
mce operon is composed of two predicted IM YrbE permeases and six homologous Mce proteins 
(MceA-F). An unlinked cytoplasmic ATPase, MceG, was first identified as the probable ATPase 
for Mce transporter systems when it was identified via genetic interaction mapping between 
Mce1 and Mce4 systems (122). MceG is now predicted to provide energy for all four Mce 
systems of Mtb (77). Bioinformatic studies identified YrbE permeases and MceG ATPase 
proteins as belonging to ABC transporter clades (77). ABC transporter permeases are integral 
membrane proteins that typically contain transmembrane domains and the YrbE proteins contain 
five to six transmembrane domains. ABC transporter permeases that function in substrate import 
(i.e., work with SBPs) also contain a highly conserved amino acid sequence, the EAA motif, 
located in the final cytoplasmic loop of the permease. The EAA motif interacts with the ABC 
transporter’s cognate ATPase. YrbE permeases also have a conserved consensus sequence in 
their cytoplasmic loop region. However, the YrbE motif sequence, EExDA, is typically located 
in the penultimate cytoplasmic loop, and its sequence is not identical to the EAA motif but does 




ABC transporter ATPases. For example, the MceG ATPase contains a Walker A and Walker B 
motifs that are necessary for ATP binding as well as the LSGGQ motif that is found within ABC 
transporter ATPases (77). MceG does differ from canonical ABC ATPases because it contains a 
unique C-terminal domain. A truncated MceG that lacks its C-terminal domain cannot restore 
ΔmceG growth on cholesterol, suggesting that this domain is important to proper functioning of 
Mce transporters; however, its exact role remains to be determined (124). MceG, has been shown 
to be important for both Mce1 and Mce4 function and stability (44, 51, 104, 122, 124). ABC 
transporters of the import clade also contain SBPs and mce operons contain mceA-F, which are 
predicted to encode SBPs. The predicted SBPs (MceA-F), the ATPase (MceG). and 
hypothesized permeases (YrbEAB) are all traditional components of an ABC transporter, which 
suggests that Mce systems are complex ABC transporters, similar to the OM lipid transport 
systems of E. coli previously discussed (Lpt, Lol, and Mla).  
Mce systems are often considered to be analogous to ABC transporters; however, they 
are much more complex. Instead of one SBP as is the case in ABC importers, Mce transporters 
have six putative SBPs (MceA-F) (77). Each Mce protein has an MCE domain, similar to the 
proteins involved in the phospholipid transport systems described in E. coli, such as MlaD. 
However, Mce proteins are themselves more complex than MlaD. Whereas MlaD only contains 
the MCE domain, Mce proteins contain a MCE domain, a Cholesterol_Uptake_Porter_1 
(CUP_1) domain that is characterized by a largely alpha-helical secondary structure, and a 
variable domain (125). Adding to Mce transporter complexity, there are two other predicted 
components of Mce transporters: Mce Associated Membrane (Mam) proteins, encoded by genes 
linked to mce operons, and Orphaned Mce Associated Membrane (Omam) proteins, encoded by 




similarity to each other and also with a type IV secretion system (T4SS) protein, VirB8 (126, 
127). VirB8 acts to stabilize and assemble the multiprotein VirB T4SS in Brucella suis and 
Agrobacteria tumefaciens (128–130). Moreover, VirB8 is currently the target of a campaign to 
find anti-virulence B. suis inhibitors (131). We hypothesize that Omam and Mam proteins 
function as a VirB8 equivalents in Mce systems. In support of this hypothesis, OmamA has been 
shown to promote the function of the Mce1 and Mce4 systems. OmamA is necessary for Mce1 
palmitic and oleic acid import and Mce4 cholesterol import, and OmamA acts to stabilize 
multiple members of the Mce1 transporter system (104, 127). We also show in the work 
described in this thesis that OmamA is required for Mce4 function and that protein levels of 
Mce4A and Mce4E decrease in the absence of omamA, which is indicative of OmamA 
stabilizing the Mce4 transporter. Another protein, LucA, similarly is important for both Mce1 
and Mce4 function, and stabilizes Mce1 transporter components (104). We hypothesize that Mce 
transporter components create a large macromolecular complex within the mycobacterial cell 
envelope because a large number of proteins have been implicated in lipid import, including 
stabilizing proteins, like Omams, that resemble the stabilizing protein, VirB8, of the large, multi-
protein VirB T4SS. 
Summary 
Lipids are essential to the lifestyle of mycobacteria, providing structure, nutrients, and 
virulence effectors. Thus, lipid biosynthesis, trafficking, import, and utilization pathways can be 
considered potential drug target for mycobacteria. However, cell wall lipids are inherently 
difficult to target as many lipids are not directly encoded, but rather are built off of other lipid 
templates, and because many lipids have overlapping functions (132). Drugs that target export of 




several campaigns to find inhibitors of cholesterol utilization as cholesterol is an important 
nutrient to Mtb during infection (88, 133). Targeting the mycobacterial lipid import systems, the 
Mce transporters, provides another possibility for inhibiting the use of lipids as nutrients to Mtb 
during infection or precursors for the synthesis of other cell wall lipids important to Mtb cell 
envelope structure and virulence. Mtb has four Mce transporters, presumably each having 
different lipid substrates. A particularly compelling drug target within Mce transporter systems 
would be a component that contributes to all four systems, such as been seen for the Omam 
proteins. However, much remains unknown about the mechanism of Mce transporters to 
rationally search for inhibitors of these systems. In this dissertation, I describe the 
characterization of the Mce4 transporter cholesterol import system of mycobacteria. In work 
described in Chapter 2, we show that individual Mce, Mam, and Omam proteins have non-
redundant roles in Mce4-dependent transport of cholesterol. Additionally, stability and mass 
spectrometry of co-immunoprecipitated Mce4A experiments provide insight into the association 
of MceG, YrbE4AB, Mce4A-F, Mam4AB, and OmamAB proteins to form a large multi-protein 
complex in the mycobacterial cell envelope. In Chapter3, I discuss continuing work to determine 
protein-protein interactions between components of the Mce4 transporter as well as initial work 
to determine important residues of transporter components. Overall, in this thesis, I provide give 
evidence to support the hypothesis (or model) that Mce transporter components function in 





A. Gram-negative bacteria have a cytosolic (inner) membrane composed of a phospholipid 
bilayer and an asymmetrical outer membrane with LPS populating the outer leaflet and 
phospholipids populating the inner leaflet. A gel-like periplasmic space that contains a thin layer 
of peptidoglycan separates the two lipid bilayer membranes. Lipoproteins, proteins that are 
anchored to membranes via a lipid moiety, can be localized to either the IM and OM. Proteins 
can also be found in all cell envelope compartments (IM, periplasm, cell wall, and OM). B. 
Gram-positive bacteria have a cytosolic membrane composed of a phospholipid bilayer, which is 
surrounded by a thick layer of peptidoglycan. Lipoproteins are anchored to the IM. Proteins can 
be found in both the IM and cell wall cell envelope compartments. C. Mycobacteria have a 
cytosolic (inner) membrane composed of a phospholipid bilayer and an asymmetrical 
mycobacterial outer membrane, populated with free lipids in the outer layer and mycolic acids in 
the inner layer. Mycolic acids also connect to a layer of arabinogalactan and peptidoglycan, 
which make up the mAGP complex within a gel-like periplasmic space. Lipoprotein are found at 
the IM but it remains to be determined if lipoproteins can localize to the OM. Proteins are 
localized to all cell compartments (IM, periplasm, cell wall, and OM); however, very few known 
examples of OM proteins have been validated (133).  
 





Figure 1. 2. LPS, Lol, and Mla transporters transport lipids between the IM and OM of E. coli  
A. The Lpt transporter transports LPS from the inner membrane to the outer leaflet of the outer 
membrane. LPS is removed from the inner membrane via the ABC transporter unit (LptBGF) 
and inner membrane transmembrane domain protein, LptC. Successive rounds of ATP 
hydrolysis push LPS through inner membrane LptBCGF complex and onto a bridge of LptA 
proteins that protect the Lipid A moiety of LPS, which connect to the outer membrane LptDE 
complex. The LptDE complex inserts the LPS into the outer leaflet of the outer membrane via an 
unknown mechanism. B. The Lol transporter transports lipoproteins from the inner membrane to 
the outer membrane. Lipoproteins are extracted from the inner membrane via via the ABC 
transporter unit (LolCDE), and are passed to a periplasmic chaperone protein, LolA, which binds 
to the acyl-lipid tails of lipoproteins. LolA then ferries the lipoprotein to the outer membrane 
lipoprotein, LolB, which inserts lipoproteins to either the inner or outer leaflet of the outer 
membrane by an unknown mechanism. C. The Mla transporter transports phospholipids between 
the inner membrane and inner leaflet of the outer membrane. Phospholipids move between an 
inner membrane complex, MlaBDEF, and an outer membrane complex, MlaA and OmpC/F, via 





Figure 1.3 E. coli phospholipid transporters contain MCE-domain containing proteins (MlaD, 
PqiB, and YebT). 
A. The Mla transporter transports phospholipids between the inner membrane and inner leaflet of 
the outer membrane. Phospholipids move between an inner membrane complex, MlaBDEF, and 
an outer membrane complex, MlaA, which is a OM lipoprotein, and OmpC/F, via the 
periplasmic chaperone protein MlaC. MlaD is an MCE-domain containing protein, and forms a 
hexameric pore through which phospholipids can travel at the inner membrane. B. A 
hypothetical model for the PqiABC transporter. It is hypothesized that PqiABC forms a 
transporter system similar to Mla. PqiA is a hypothetical permease protein and PqiB is an MCE-
domain containing protein. PqiB contains three MCE-domains that stack upon one another and 
six PqiB monomers hexamerize to form a pore as visualized by cryo-EM (76). PqiC is predicted 
outer membrane lipoprotein. How PqiA, PqiB, and PqiC interact has yet to be determined and an 
ATPase to power the system have yet to be identified. C. A hypothetical model for the YebST 
(LetAB) transporter. YebS is a hypothetical permease protein and YebT is an MCE-domain 




upon one-another as shown by cryo-EM and crystal structures. The stacked MCE-domains form 
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CHAPTER 2: EVIDENCE FOR THE MYCOBACTERIAL MCE4 TRANSPORTER 
BEING A MULTIPROTEIN COMPLEX 
Introduction 
Lipids play important roles in bacterial physiology, where they serve as nutrient sources 
or as components of the protective cell envelope (1, 2). However, lipid transport across the 
bacterial cell envelope remains a poorly understood process (3–5). In diderm (two membrane-
containing) bacteria, such as Gram-negative Escherichia coli, or Actinobacteria, such as 
mycobacteria, there is a cytoplasmic, inner membrane (IM) and an outer membrane (OM). 
Although the OMs of Gram-negative bacteria and Actinobacteria have different compositions, in 
both cases they are hydrophobic lipid barriers that are separated from the IM by a hydrophilic 
periplasm (5–7). Thus, lipids moving across the cell envelope, in either direction (in or out), 
traverse an environment in which they are not soluble, necessitating specialized transport 
systems. In E. coli, macromolecular systems for transporting lipids across the cell envelope to 
the OM have been identified, including the Lpt transporter that delivers lipopolysaccharide (8, 9) 
and the Lol system that delivers lipoproteins (10). Both Lpt and Lol systems involve a dedicated 
ATP-Binding Cassette (ABC) transporter in the IM. Most recently, transporters that traffic 
phospholipids to or from the inner leaflet of the E. coli OM were identified. A notable feature of 
E. coli phospholipid transporters is that they involve a Mce-domain-containing protein (11, 12). 
So far, the best characterized of these Mce transporters in E. coli is the Mla system, which is 




In the Mla system, the Mce-domain-containing protein is the IM-anchored periplasmic 
protein MlaD, which acts as a solute-binding protein (SBP) that binds the phospholipid (13, 14, 
16). SBPs are periplasmic proteins that deliver solutes to ABC transporters (17). There is 
evidence for MlaD and other E. coli Mce-domain proteins (YebT/LetB and PqiB), which 
function in separate phospholipid transport pathways, forming a homo-hexameric tunnel (13, 14, 
18, 19) for translocating and delivering the phospholipid to the core ABC transporter 
components (an IM permease MlaE and a cytoplasmic ATPase MlaF) (16). The Mla system also 
involves the cytoplasmic MlaB protein that stabilizes the ATP-binding domain of MlaF and a 
periplasmic MlaC protein that acts as a chaperone (15, 20, 21) ferrying phospholipids between 
MlaD and an OM lipoprotein, MlaA (20, 22).  
The very first Mce protein discovered was the Mce1A protein of Mycobacterium 
tuberculosis, which was initially identified as a protein that promotes “Mammalian cell entry” 
when produced in heterologous bacteria (23). Only later were Actinobacterial Mce proteins 
recognized to function in lipid transport (24–27). The best characterized Actinobacterial Mce 
system is the Mce4 transporter of Rhodococcus jostii and mycobacteria that imports cholesterol 
from the environment into the bacterial cytoplasm (2, 24, 25). M. tuberculosis encodes four Mce 
transporters, Mce1-4, and the model organism mycobacteria, M. smegmatis, encodes six Mce 
transporters (28, 29). It is likely that each of the mycobacterial Mce transporters imports different 
lipids. For instance, the Mce1 transporter imports oleic and palmitic fatty acids whereas the 
Mce4 transporter imports cholesterol (25–27). Fatty acids and cholesterol are metabolized by M. 
tuberculosis during infection and both Mce1 and Mce4 contribute to the pathogenesis of M. 




Mycobacterial Mce transporters appear to be more complex than E. coli Mce-domain 
containing transporters (Figure 2.1). The added complexity may reflect unique barriers to lipid 
transport across the mycobacterial cell envelope, which includes a covalent network of 
peptidoglycan and arabinogalactan and a unique Mycobacterial Outer Membrane (MOM) (6). 
Each mycobacterial mce locus has an operon made up of genes encoding predicted permeases, 
YrbEA and YrbEB, and six Mce proteins (MceA-F) (Figure 2.1) proposed to function as SBPs 
(not just one as in typical ABC transporters) (28). Moreover, compared to MlaD, which is 
composed of a transmembrane domain followed by a Mce domain, Mce proteins of 
mycobacterial systems are larger, possessing beyond the Mce domain a second conserved 
domain, Mce4_CUP1, followed by a variable region (Figure 2.2). Immediately adjacent to nearly 
all mce operons are genes encoding Mce Associated Membrane (Mam) proteins, which have a 
transmembrane domain at their N-terminus followed by a periplasmic domain. In addition, there 
are Orphaned Mce Associated Membrane (Omam) proteins with predicted structural similarity to 
Mam proteins that are encoded from genes that are located distal to mce operons (37). We 
previously established that one of these Omam proteins, OmamA, contributes to the function of 
multiple Mce transporters (37). Finally, MceG is an ATPase that is predicted to work with all the 
Mce transporters of mycobacteria (32, 38). Apart from MceG, which is cytoplasmic, all of these 
proteins are demonstrated or predicted to reside in the cell envelope (28, 33, 39, 40). How these 
components interact and work together to import lipids through the mycobacterial cell envelope 
is largely unknown.  
Here, we investigated a set of M. smegmatis mce4, mam4, and omam mutants and 
demonstrated non-redundant roles for individual components in cholesterol transport using 




Omam proteins in mycobacteria proved to be required for cholesterol import. While OmamA and 
OmamB contributed to Mce4 cholesterol import, OmamC,D,E, and F were not required. We then 
demonstrated that Mce4A and Mce4E protein levels are reduced in every one of the individual 
mce4, mam4, and omam mutants that had cholesterol uptake defects. Because the stability of 
proteins in multiprotein complexes often relies on protein interactions, this dependence of 
Mce4A and 4E levels on the presence of individual Mce4, Mam4, and Omam proteins suggests 
an extensive network of interactions that serve to assemble and/or stabilize a multiprotein Mce4 
transporter complex. Further, using immunoprecipitation-mass spectrometry (IP-MS) to identify 
Mce4A-associated proteins, we identified Mce4B-F, YrbE4A, YrbE4B, Mam4A, Mam4B, 
OmamA, OmamB, and MceG. Together, our results provide the first evidence for interactions 
between Mce4 transporter proteins and for Mce transporters being large multiprotein complexes 
in the mycobacterial cell envelope.  
Results 
Individual Mce4 and Mam4 proteins have required functions in Mce4 transport of 
cholesterol  
As is the case for all Mce transporter systems, the mce4 operon encodes six Mce proteins 
(Mce4A-F) (Figure 2.1), each with approximately 20% identity to one another (Table 2.1). To 
address the functions of individual Mce proteins, we generated an in-frame, unmarked deletion 
in mce4A (codons for aa 7-392 were deleted, Mce4A is 400aa) in the M. smegmatis genome. We 
also constructed an in-frame, unmarked deletion of mce4E (codons for aa 27-363 were deleted, 
Mce4E is 382aa). Along with Mce4A, we chose to study Mce4E because in nearly every 
mycobacterial Mce system, the MceE protein is a predicted lipoprotein, while all the other Mce 




contributions of Mce4A and Mce4E to cholesterol import, the Δmce4A or Δmce4E mutants were 
each tested for growth in media containing cholesterol as the sole carbon source (Figure 2.3A, 
2.3B). The ability of metabolically active mycobacteria to reduce resazurin dye, as measured by 
fluorescence, was used to monitor growth in culture (45). While the parental wildtype (WT) M. 
smegmatis strain grew in M9 media with cholesterol as the sole carbon source, the Δmce4A 
mutant and the Δmce4E mutant exhibited little to no growth. In parallel, we tested Δmce4A or 
Δmce4E strains carrying multicopy plasmids expressing the WT copy of the deleted mce gene 
from the constitutive hsp60 promoter. The growth defect in cholesterol was reversed in these 
complemented strains, demonstrating that the phenotype is due to the mutation of the single gene 
(Figure 2.3A, 3.2B). All strains grew equally well on media with glucose and glycerol as carbon 
sources, eliminating the possibility that the mutants have a more general growth defect (Figure 
2.4A, 2.4B). We further tested our Δmce4A or Δmce4E mutants and complemented strains for 
their ability to import 14-C radiolabeled cholesterol (Figure 2.3F). WT, mutant, and 
complemented strains were incubated in M9 media with 14-C radiolabeled cholesterol for 3hrs, 
after which time the mycobacterial strains were washed and the radioactivity taken up by the 
cells was measured. The level of radiolabeled cholesterol taken up by the Δmce4A or Δmce4E 
mutants was significantly reduced compared to WT and the complemented strains (Figure 2.3F).  
Together, these experiments demonstrated that Mce4A and Mce4E are each individually required 
for cholesterol uptake. 
We also constructed a larger Δmce4E deletion mutant that extended to the second to last 
codon (codons for aa 27 to 381 deleted). This larger deletion Δmce4E mutant was also unable to 
grow on or uptake cholesterol (Figure 2.3B, 2.3F).  However, with this mutant the same mce4E 




radiolabeled cholesterol, although a plasmid expressing both mce4E and mce4F was able to 
reverse the cholesterol defects (Figure 2.3B, 2.3F). These results indicated that the larger 
deletion has a polar effect on the downstream mce4F and it indicates that Mce4F is additionally 
required for cholesterol uptake. As the stop codon in mce4E and start codon in mce4F are 
immediately adjacent to one another, we suspect that the polar effect resulted from the larger in-
frame Δmce4E deletion, hereafter called Δmce4Epolar, disrupting translation initiation of the 
downstream mce4F. For the remainder of this report, this larger Δmce4Epolar mutant strain 
carrying the mce4E complementation plasmid used above (i.e. complemented for the mce4E 
deficiency only) will be referred to as a mce4F* mutant.  All the mce4Epolar mutant strains grew 
equally well on glucose and glycerol (Figure 2.4B). 
 We also investigated the roles of the Mam4A and Mam4B proteins in cholesterol uptake. 
Mam proteins (Mce associated membrane proteins) are encoded, often in pairs, at the end of mce 
loci. We constructed an in-frame deletion of mam4A (codons for aa 10-209 were deleted, 
Mam4A is 210 aa). This Δmam4A mutant was unable to grow on cholesterol or uptake 
radiolabeled cholesterol as compared to WT (Figure 2.3C, 2.3F). However, similar to the 
Δmce4Epolar mutation, the Δmam4A in-frame deletion had a polar effect on mam4B. Introduction 
of a multicopy plasmid expressing mam4A alone was unable to complement the mutant 
phenotypes, while a multicopy plasmid expressing mam4AB reversed the phenotypes. Further, 
expression of mam4B alone in the Δmam4Apolar mutant was unable to rescue cholesterol growth 
and import defects, but when the Δmam4Apolar mutant carried pairs of multicopy and single copy 
(i.e. integrating) plasmids that in combination express both mam4A and mam4B, cholesterol 
defects were fully restored.  These experiments demonstrated that both Mam4A and Mam4B are 




to demonstrate that the plasmids carrying mam4A or mam4B express functional protein (Figure 
2.3C, 2.3F). For the rest of this report, the Δmam4Apolar mutant carrying the multicopy mam4A 
plasmid will be referred to as a mam4B* mutant and the Δmam4Apolar mutant with multicopy 
mam4B plasmid will be referred to as a mam4A* mutant. All the mam4Apolar mutant strains grew 
equally well on glucose and glycerol (Figure 2.4C).  
 Together, these results demonstrated that Mce4A,E,F, and Mam4A,B each have essential 
functions in cholesterol uptake. The results further indicated that, at least under the conditions 
tested, orthologous genes from other mce operons (e.g. mce1A) are unable to compensate for 
mce4 loci genes.  
OmamA and OmamB proteins contribute to Mce4 transport of cholesterol, but OmamC-F 
do not 
In addition to the Mam proteins that are encoded by genes at the ends of mce loci, we 
previously identified Orphaned Mam proteins (Omam) in mycobacteria that are encoded by 
genes distal to mce operons (28, 37). Mam and Omam proteins have predicted structural and 
membrane topology similarity, and studies of omamA mutants of M. smegmatis and M. 
tuberculosis demonstrate a role for OmamA in Mce4 and Mce1 transporters (37). There are 10 
omam genes in the M. smegmatis genome (omamA-J), of which five are conserved in M. 
tuberculosis (omamA-E) (37). Genes encoding Omam proteins are often encoded in pairs, as is 
the case for most mam genes. To determine if the other Omam proteins beyond OmamA are 
similarly involved in Mce transport, we evaluated whether the additional M. smegmatis Omams 
that are conserved in M. tuberculosis (M. smegmatis OmamB-E) are required for cholesterol 
uptake.  We constructed an in-frame, unmarked deletion of omamB in M. smegmatis as well as 




double mutants. As seen with the ΔomamA mutant, ΔomamB mutants had a defect in growth on 
and in uptake of radiolabeled cholesterol as compared to WT, and these phenotypes were 
reversed when an omamB complementation plasmid was present (Figure 2.3D, 2.3G). The 
ΔomamA and ΔomamB mutants exhibited normal growth on glucose and glycerol comparable to 
WT (Figure 2.4D). Unlike ΔomamA and ΔomamB mutants, the other omam mutants (ΔomamCD 
and ΔomamEF) grew on and imported cholesterol at WT levels, indicating that not all Omams 
are required for cholesterol uptake (Figure 2.3E). 
Effects of Mce, Mam and Omam proteins on the abundance of Mce4A and Mce4E  
Given the many Mce, Mam, and Omam proteins required for cholesterol import, all of 
which are predicted to localize to the cell envelope (28, 33, 39, 40), we hypothesized that some 
or all of these proteins interact in a Mce4 transporter complex. Using antibodies raised to unique 
peptides of Mce4A and Mce4E, we confirmed a cell envelope location of these specific Mce 
proteins by immunoblotting subcellular fractions of M. smegmatis (Figure 2.5C). Mce4A and 
Mce4E were primarily localized to the cell wall fraction where the MspA porin resides with 
lesser amounts associated with the membrane fraction, where the integral inner membrane 
protein SecY localizes (Figure 2.5C, D, E). These antibodies are specific for their respective 
Mce4 proteins and do not cross-react with Mce proteins of other transporters, as shown by 
immunoblot analysis of mutant strains (Figure 2.5A, B).  
A common property of multiprotein complexes is that the stability of individual proteins 
in the complex depends on interactions among the components (46–48). Therefore, as an 
approach to predict proteins in a Mce4 transporter complex, we determined if the steady state 
levels of Mce4A and Mce4E depend on individual Mce, Mam or Omam proteins by performing 




cholesterol uptake defects. We started by testing the effect of Mce4E on Mce4A protein levels 
(Figure 2.6A). Immunoblotting with anti-Mce4A antibodies of WT, Δmce4E mutant and the 
complemented strain WCL revealed reduced levels of Mce4A in the Δmce4E mutant compared 
to the WT and the complemented strain. The reciprocal experiment reinforced the relationship 
between Mce4A and Mce4E protein levels (Figure 2.6B). WCL of the Δmce4A mutant had 
reduced levels of Mce4E compared to the WT and complemented strains. We also assessed 
Mce4A levels in the mce4F* mutant. Here too, the level of Mce4A in WCL lysate was reduced 
in the mce4F* mutant (Figure 2.6A).  Given the nature of our mce4F* mutant (i.e. the 
Δmce4Epolar mutant carrying a mce4E complementation plasmid) it was not possible to determine 
the effect of Mce4F on Mce4E levels.  Next, we tested if Mam4A and Mam4B have an effect on 
Mce4A and Mce4E levels. WCL of mam4A* and mam4B* mutants also exhibited reduced 
Mce4A and Mce4E protein levels compared to WT and complemented strains (Figure 2.6A, 
2.6B). Finally, Mce4A and Mce4E protein levels were also reduced in ΔomamA and ΔomamB 
mutants compared to WT and complemented strains (Figure 2.6A, 2.6B). GroEL levels were 
used as a protein loading control in these experiments. These results indicated that the levels of 
Mce4A and Mce4E are reduced when any Mce4A,E,F, Mam4A,B, or OmamA,B protein is 
absent.  These results are consistent with a network of interactions among these proteins that 
either leads to assembly or stability of Mce4A and Mce4E containing complexes.  
Conserved lipobox cysteine of Mce4E is not necessary for Mce4 transporter function 
The above results suggested that individual Mce4 proteins associate and that each is 
required to play a specific role in cholesterol import. The 5th Mce protein (MceE) encoded by 
nearly every mce locus is distinct from other Mce proteins in being a predicted lipoprotein (28) 




cysteine that is the site of lipid modification (Figure 2.7A). In contrast to MceE, none of the 
other five Mce proteins possess a lipobox. We hypothesized that the role of MceE in the Mce4 
transporter would depend on the lipobox cysteine of Mce4E, potentially because the lipid 
modification on Mce4E would tether the protein to the IM or mycobacterial OM as a prerequisite 
for assembly, stabilization or proper localization of the Mce4 transporter complex. Using site 
directed mutagenesis, we constructed a plasmid expressing a mutant mce4EC16A which will 
encode for a Mce4E with the lipobox cysteine substituted with an alanine (Figure 2.7B). This 
substitution eliminates the lipobox motif and converts the export signal peptide of Mce4E to a 
standard Sec signal peptide (41, 42). To our surprise, Mce4EC16A was functional. Introduction of 
a plasmid carrying the mce4EC16A allele into the Δmce4E mutant fully restored growth on 
cholesterol and radioactive cholesterol uptake (Figure 2.7C, 2.7D). Additionally, Mce4A protein 
levels were comparable to WT levels in the presence of Mce4EC16A (Figure 2.7E). In contrast to 
our predictions, these results indicated that Mce4E does not require lipidation for its function in 
the Mce4 transporter, despite conservation of a lipobox cysteine across MceE proteins of 
mycobacterial species.  
Mce4A and Mce4E interact 
The finding that Mce4A and Mce4E are mutually required to stabilize one another 
suggested an interaction between the proteins. To test for an interaction between Mce4A and 
Mce4E in mycobacteria, we performed a co-immunoprecipitation experiment from WCL of a 
Δmce4A mutant strain engineered to produce Mce4A-HA fusion protein. Following 
immunoprecipitation with anti-HA agarose beads the immunoprecipitated sample was 
immunoblotted for the presence of native Mce4E protein using anti-Mce4E antibody. Mce4E 




not recovered when the HA immunoprecipitation was performed on the WCL of a strain 
producing untagged Mce4A (Figure 2.8A). Further evidence for an interaction between Mce4A 
and Mce4E was obtained with the reciprocal co-immunoprecipitation experiment. Native Mce4A 
co-immunoprecipitated with Mce4E-HA (Figure 2.8B). As a control, we also immunoblotted the 
immunoprecipitate for MspA, a cell wall porin (49). MspA did not co-immunoprecipitate with 
Mce4E-HA (Figure 2.8B), confirming the specificity of the Mce4A-Mce4E interaction. The 
interaction between Mce4A and Mce4E was observed regardless of whether multicopy or single 
copy (i.e. chromosomally integrated) expression plasmids were used to produce the HA-tagged 
proteins (Figure 2.8C, 2.8D). The HA tagged Mce4A and Mce4E proteins were functional as 
shown by their ability to promote cholesterol utilization when expressed in the Δmce4A and 
Δmce4E strain backgrounds (Figure 2.9).  
Immunoprecipitation-Mass Spectrometry (IP-MS) identifies additional components of a 
Mce4A-containing complex 
To identify additional proteins that exist in a complex with Mce4A, we repeated the 
Mce4A-HA immunoprecipitation and analyzed the samples using liquid chromatography 
coupled to tandem mass spectrometry (LC-MS/MS). Immunoprecipitated samples prepared from 
strains expressing Mce4A-HA or HA only as a control (Figure 2.8C) were subjected to trypsin 
digestion followed by LC-MS/MS. Label free quantitation (LFQ), using area under the curve, 
was performed on proteins identified by > two unique peptides and significant differences in 
LFQ intensity of proteins in the Mce4A-HA immunoprecipitation versus the control were 
determined using Student’s t-test. Proteins with a p-value <0.05 and a minimum 2-fold 
enrichment (log2 = 1.0) in the Mce4A-HA immunoprecipitate compared to control were 




(28-481-fold) in the Mce4A-HA immunoprecipitation were all six of the Mce4 proteins (Mce4A-
F). Six additional proteins with roles in Mce4 transport of cholesterol, all of which are 
demonstrated or predicted to reside in the cell envelope, met our criteria for interacting with 
Mce4A-HA: YrbE4A, YrbE4B, Mam4A, Mam4B, OmamA, and OmamB. In addition, the 
cytoplasmic ATPase, MceG was also identified as interacting with Mce4A-HA (Figure 2.10, 
APPENDIX I). All of these additional proteins met our cutoffs for an interaction; however, the 
level of enrichment was less than what was observed for the Mce4A-F proteins, which may 
reflect less stable interactions. Combined with the dependence of Mce4A and Mce4E stability on 
the presence of individual Mce4, Mam4, OmamA, and OmamB proteins, the identification of 
these proteins as associating with Mce4A by IP-MS indicates that this collection of proteins 
work together to assemble and/or function as multiprotein Mce4 transporter complexes. In 
addition, five Mce1 transporter proteins (Mce1C,D,E,F, and Mam1A) met our significance 
cutoffs and were identified as associating with Mce4A (Figure 2.10, APPENDIX I).  
Discussion  
How Mce transporters work to import lipids in mycobacteria is unknown. Here, we 
constructed a set of mutants and used them to demonstrate the requirement of individual Mce4, 
Mam4, OmamA, and OmamB proteins for the cholesterol uptake function of the Mce4 
transporter (Figure 2.3). We further demonstrated that not all Omam proteins are required for 
cholesterol uptake by M. smegmatis, at least under the conditions tested (Figure 2.3). Moreover, 
we demonstrated that the individual Mce4, Mam4, OmamA, and OmamB proteins are required 
for stabilization of Mce4A and 4E proteins (Figure 2.6). As this was the case for every protein 
associated with the Mce4 transporter system that we tested, it suggests a network of interactions 




complexes. Additionally, through IP-MS experiments we identified the Mce4A protein as 
interacting with every single Mce, Mam, and Omam protein required for the Mce4 transporter to 
import cholesterol (Figure 2.10). Together, these results argue for the Mce4 transporter 
functioning as a large multiprotein complex.   
Mce4 transporter components required for cholesterol growth and uptake 
By inactivating mce4A, mce4E, mce4F, mam4A, and mam4B, we showed that 
Mce4A,E,F, and Mam4A,B proteins are necessary for M. smegmatis to grow on cholesterol and, 
more specifically, to uptake cholesterol (Figure 2.3). Previously, García-Fernández et al. (50) 
created in-frame mutants of all the genes in the mce4 locus and demonstrated them to be 
defective for growth on cholesterol. In that same study, a Δmce4A mutant was demonstrated to 
be unable to uptake radiolabeled cholesterol. However, the other mutants in that study were not 
similarly evaluated for cholesterol uptake (50), which is an important detail since growth on 
cholesterol reflects more events than just cholesterol uptake. Furthermore, the process of Mce4-
dependent import of cholesterol was previously proposed to involve dissociable events (i.e. entry 
into cell envelope and translocation across the IM) (27). In fact, a M. tuberculosis Δmam4B::hyg 
mutant is reported as being competent in cholesterol uptake but defective for growth in 
cholesterol (27). However, in contrast to this result in M. tuberculosis, our M. smegmatis 
Δmam4B* mutant exhibited both a cholesterol growth defect and uptake defect (Figure 2.3). 
While these different outcomes remain to be resolved, the cholesterol uptake defect we observed 
with our Δmam4B* mutant is consistent with our finding that the levels of Mce4A and Mce4E 
proteins, both of which are themselves required for cholesterol uptake, were severely reduced in 
the Δmam4B* mutant (Figure 2.6). Taking advantage of the cholesterol utilization and uptake 




cysteine in Mce4E. We had hypothesized that lipidation of Mce4E would be required for its 
proper location and function in the transporter. To our surprise, the lipobox cysteine was not 
required for Mce4E function, at least under the conditions tested (Figure 2.7). The subcellular 
localization of the Mce4EC16A variant in comparison to WT Mce4E was also unchanged (data not 
shown), which is consistent with our finding that the mutation did not eliminate Mce4E function. 
We also evaluated the role of Omam proteins, which are not linked to mce operons, in the 
Mce4 transporter function of cholesterol uptake. Despite relatively low sequence similarity, 
Omam proteins have predicted structural and membrane topology similarity to Mam proteins and 
we previously showed that OmamA is required for Mce4 uptake of cholesterol (37). OmamA 
also has a role with the Mce1 transporter (37, 51). In the absence of OmamA, Mce1 proteins as 
well as Mce4 proteins, with the latter being shown in this report for the first time (Figure 2.6), 
are unstable (37). These results suggest that Omam proteins have roles in multiple Mce 
transporters. There are 10 omam genes (omamA-omamJ) in M. smegmatis, 5 (omamA-omamE) of 
which are conserved in M. tuberculosis. Besides OmamB of M. tuberculosis being shown to be 
required for Mce1 transporter uptake of fatty acids (51), other Omams have not been studied. 
Here, we assessed the role of the 5 Omams that are conserved in M. tuberculosis (OmamA-E) as 
well as OmamF in M. smegmatis. Only ΔomamA and ΔomamB mutants were impaired for 
growth on cholesterol and in cholesterol uptake (Figure 2.3D, 2.3E, 2.3G).   
The structural prediction program Phyre 2 (52) identified similarity between Omam and 
Mam proteins with VirB8 proteins from Brucella suis and Agrobacteria tumefaciens (37). VirB8 
is important for the stability and function of the large multiprotein type IV secretion system 
(T4SS) complexes (46–48, 53). We hypothesize that Omam and Mam proteins function as VirB8 




specifically, we hypothesize that Mam proteins stabilize the Mce transporter with which their 
genes are linked in the genome; whereas, OmamA and OmamB work with and stabilize multiple 
or all Mce transporters. This hypothesis is supported by the observation that OmamA and 
OmamB affect Mce1 and Mce4 transport but Mam4B only affects Mce4 transport (27, 37, 51). 
Due to the lack of knowledge about the other Mce transporters it is not yet possible to test if the 
functions of OmamA and OmamB extend to them, as well. As omamCD and omamEF mutants 
were fully competent in cholesterol uptake (Figure 2.3E), we speculate that these and the other 
remaining Omams likely stabilize multiprotein complexes, other than Mce transporters, in the 
mycobacterial cell envelope.  
Interactions among Mce4 transporter proteins  
With the exception of the cytoplasmic MceG ATPase, a cell envelope location is either 
predicted or proven for all the proteins so far identified as playing roles in Mce transporters 
(Figure 2.5) (28, 33, 39, 40). Similar to lipid transporters of Gram-negative bacteria, we 
hypothesized that Mce4 transporters would exist as multiprotein complexes in the cell envelope 
(8–10, 16, 18–20, 22). For proteins that interact in a complex, it is common for them to stabilize 
one another (46–48). As an approach to predict proteins that associate in a Mce4 transporter 
complex, we used anti-Mce4A and anti-Mce4E antibodies to examine the levels of Mce4A and 
Mce4E in our collection of mce4, mam4, omamA, and omamB mutants. In every case, the levels 
of Mce4A and Mce4E were reduced and these phenotypes could be complemented (Figure 2.6). 
These results suggest the existence of an extensive network of interactions between Mce4A,E,F, 
Mam4A,B, and OmamA,B proteins that may serve to assemble and/or associate in multiprotein 
Mce4 transporter complexes. We were unable to assess the stability of additional Mce4-




results so far, we consider it likely that all of the proteins involved in Mce4 transport of 
cholesterol are dependent on one another for stability.  
 To further explore interactions between Mce4, Mam4, OmamA, and OmamB proteins, 
we performed co-immunoprecipitation experiments. First, by immunoprecipitating Mce4A or 
Mce4E and immunoblotting for the presence of the other Mce4 protein, we were able to 
demonstrate that Mce4A and Mce4E interact (Figure 2.8). We subsequently extended this 
analysis and performed IP-MS on Mce4A immunoprecipitated samples. In the IP-MS data, we 
identified all mce4 locus encoded proteins (YrbE4A,B, Mce4A-F, Mam4A,B) as being 
significantly enriched and meeting the significance cutoffs for an interaction in the Mce4A 
immunoprecipitation versus the control. In addition, we identified OmamA and OmamB as 
interacting with Mce4A. The Mce4A-F proteins were 6 of the 7 most enriched proteins in the 
immunoprecipitated samples (Figure 2.10, APPENDIX I). Based on structural studies of E. coli 
Mce-domain containing proteins, which form homohexameric rings (13, 14, 18, 19), we 
speculate that the Mce4A-F may form highly stable heterohexameric rings or that each Mce 
protein forms a homohexameric ring that stacks on-top of one another to form a highly stable 
complex. The cytoplasmic ATPase, MceG, was also identified as associating with the cell 
envelope localized Mce4A (Figure 2.10), indicating the existence of a stable complex that spans 
the IM. While all of the proteins were previously assumed to work together to import cholesterol, 
this is the first time any of these proteins were demonstrated to associate with one another. Given 
the many proteins identified as associating with Mce4A, we consider it unlikely that they all 
participate in direct protein-protein interactions with Mce4A. Instead, we suspect they are 
members of large complexes in which Mce4A is a component. In addition, it is currently not 




in which Mce4A participates (such as an assembly complex and a separate structural transporter 
complex). Future studies will be needed to define the nature of the associations with Mce4A. 
 The IP-MS analysis also identified five Mce1-associated proteins (Mce1C-F and 
Mam1A) as interacting with Mce4A (Figure 2.10). This result indicates the potential for 
interactions between Mce systems. However, biological significance of such interactions remains 
to be determined since, at least under the conditions employed in our mutant analysis, there was 
no indication that Mce1 components can compensate for loss of the specific Mce4 or Mam4 
proteins we investigated (Figure 2.3). Finally, there were additional proteins, besides Mce-
related proteins, that met our criteria for associating with Mce4A (Figure 2.10, APPENDIX I). 
Although future studies are required to validate these interactors, it is possible that these proteins 
also play roles in Mce transporters.  
LucA was the one protein that was previously reported to function in cholesterol uptake 
by the Mce4 transporter that we did not identify in IP-MS. In M. tuberculosis, LucA is required 
for lipid uptake by Mce4 and Mce1 transporters and using a bacterial two-hybrid system a 
domain of LucA was found to interact with Oman and Mam proteins (27). It is possible that 
LucA is not a stable member of the transporter complex and instead has a more transient 
interaction, perhaps in regulation or assembly of the transporter, or has a role specific to Omam 
and Mam proteins.  
 In summary, in this report we demonstrated individual contributions of Mce4, Mam4, and 
Omam proteins in cholesterol uptake and for the first time identified associations between these 
proteins. Our data indicate that the Mce4 transporter is a stable, multiprotein complex involving 
a minimum of 13 proteins that function together to import cholesterol. The added complexity of 




Gram-negative bacteria may reflect the need for a system that can accommodate the unique 
challenges posed by the mycobacterial cell wall.  While further studies are needed to address the 
issue of direct protein-protein interactions and whether all the proteins found to associate with 
Mce4A reflect Mce4A subcomplexes or a single large complex remain to be resolved, our data 
provides important evidence for Mce transporters being another example of a multiprotein 
complex built to transport lipids across the bacterial cell envelope.   
Materials and Methods 
Bacterial strains and plasmids 
In this study, we used the bacterial strains listed in Table 2.2 and plasmids listed in Table 
2.3. Primers used for plasmid construction are listed in Table 2.4.  
Bacterial growth conditions 
M. smegmatis liquid cultures were grown at 37°C in either Middlebrook 7H9 broth (BD 
Difco) supplemented with 0.2%glucose, 0.5%glycerol and 0.05% Tween 80 (Fisher), Mueller 
Hinton (BD Difco) media supplemented with 0.05% Tween 80, M9 media supplemented with 
0.2%glucose, 0.5%glycerol, and 0.05% Tyloxapol (Sigma), or M9 media supplemented with 
0.5mM cholesterol stock solution and 0.05% Tyloxapol. M9 media was prepared as follows: 1 L 
dH2O, 12.8 g Na2HPO4, 3 g KH2PO4, 0.5 g NaCl, 1 g NH4Cl, 25 µL 1 M CaCl2, 500 µL 1 M 
MgSO4, and 2.5 ml 10% Tyloxapol. To make the cholesterol stock solution, cholesterol was 
solubilized in cyclodextrin, as previously described (37). Briefly, 1g methyl-ß-cyclodextrin 
(Sigma) was dissolved in 11mL PBS (0.09g mL−1) and heated to 80°C with continuous stirring. 
30 mg cholesterol (Sigma) was dissolved in 400μL 2:1 isopropanol/chloroform. The cholesterol 




cooled slowly and filtered sterilized. M. smegmatis was grown at 37°C on Middlebrook 7H10 
(BD Difco) agar plates supplemented with 0.2% glucose, 0.5% glycerol and 0.05% Tween 80. 
Plasmids were maintained in M. smegmatis with appropriate antibiotics for selection in either 
liquid culture or on plates (50ug/ml hygromycin (Roche), 20 ug/ml kanamycin (Sigma). 
E. coli DH5α was grown at 37°C in Luria Bertani (LB) broth (Fisher) or on LB agar 
plates. Plasmids were maintained in E. coli with appropriate antibiotics for selection in either 
liquid culture or on plates (150ug/ml hygromycin (Roche), 50 ug/ml kanamycin (Sigma)). 
M. smegmatis mutant construction 
The M. smegmatis unmarked Δmce4A mutant was created by two-step allelic exchange, 
as previously described (54). Briefly, the mce4A knockout suicide plasmid, containing a 
hygromycin-resistance marker, a sacB counter-selectable marker, and flanking regions for 
mce4A. The plasmid was transformed into M. smegmatis strain mc2155, and the first 
recombination event was selected for by resistance to hygromycin. Bacteria in which a second 
recombination event occurred were selected by plating on 7H10 Middlebrook agar supplemented 
with 0.2% glucose and 4.5% sucrose.  
The M. smegmatis unmarked Δmce4E, Δmce4Epolar, Δmam4Apolar, ΔomamB, ΔomamCD, 
and ΔomamEF strains were created using recombineering as previously described (55). Briefly, 
recombineering plasmids were digested with restriction enzymes to create a linear fragment 
containing the upstream flank, hygromycin resistance cassette, and downstream flank. This linear 
DNA fragment was transformed via electroporation into mc2155 strain containing the 
recombinase plasmid, pJV53. Double cross-over allelic exchange recombinants were selected for 




passaging 3‐4 times in the absence of kanamycin. Plasmid cured strains were then transformed 
with the resolvase expressing pMP854 plasmid, to remove the hygromycin marker, which is 
flanked by res sites in the deletion cassette. All mutants were confirmed using Sanger 
Sequencing (Genewiz).  
Cholesterol growth assay 
Cholesterol growth assays were performed as previously described (37). M. smegmatis 
strains were grown to OD 1 in M9 media supplemented with 0.2% glucose, 0.5% glycerol, and 
0.05% Tyloxapol. Strains were washed 3X by pelleting cells by centrifugation at 3000 x g for 
10min at 4C and resuspending the pellets in 10ml in M9 + Tyloxapol (no carbon). After 
washing, cells were diluted in M9+Tyloxapol (no carbon) to 105 cfu/ml and 100l were plated 
into 96 well plates with M9 containing 0.2% glucose and 0.5% glycerol or 0.5mM cholesterol 
stock solution. Plates were incubated shaking at 37°C overnight, after which resazurin (Sigma) 
was added to a final concentration 0.0125 mg mL−1. Florescence was monitored every hour by a 
Spectramax M2 using hv=544 nm excitation and hv=590 nm emission (45). 
Cholesterol uptake assay 
Cholesterol uptake assays were performed as previously described (26, 37). Briefly, M. 
smegmatis strains were grown to OD600 1 in M9 media supplemented with 0.2% glucose, 0.5% 
glycerol, and 0.05% Tyloxapol. Strains were washed 3X by pelleting cells by centrifugation at 
3000 x g for 10min at 4C and resuspending the pellets in 10ml in M9 + Tyloxapol (no carbon). 
After the final wash, strains were resuspended in M9 + 0.05% Tyloxapol (no carbon) to an 




incubated for 3 hours at 37°C. After incubation, cells were pelleted and washed three times with 
M9 + Tyloxapol, and cell associated radioactivity was measured by scintillation counter. 
Mce4A and Mce4E antiserum production 
Antipeptide antibodies for Mce4A and Mce4E in M. smegmatis were prepared by using 
peptides specific for each of the proteins. The peptides were synthesized, conjugated to keyhole 
limpet hemocyanin (KHL) and used to immunize New Zealand White rabbits that are Specific 
Pathogen-Free using Titermax Gold adjuvant at Pierce Custom Antibody Services (Rockton, IL). 
For anti-Mce4A antibodies, the peptide C-DAPATLQFLFNGAFAERDDF was used. For anti-
Mce4E antibodies, the peptide C-SGQAADPFKIPPGTA was used. Antibodies were purified by 
affinity chromatography.  
Immunoblotting 
Equal protein amounts, as determined by Bicinchonic acid assay (Pierce, ThermoFisher, 
Waltham, MA), for all fractions and strains were separated by SDS‐PAGE and transferred to 
nitrocellulose membranes. Proteins were detected using the following antibodies: Mce4 proteins 
were detected using anti-Mce4A (1:500), anti-Mce4E (1:500), and anti‐HA (1:25000) (Covance). 
GroEL2 was detected using an anti‐HIS (1:10000) (Abgent) antibody, as previously described 
(56), which recognizes a string of histidines in M. smegmatis GroEL2. MspA was detected using 
anti-MspA (1:2000) antibody gifted from Dr. Michael Niederweis. Anti‐mouse and Anti‐rabbit 
IgG conjugated HRP (1:25000) (Biorad) were used as secondary antibodies, as appropriate. HRP 
signal was detected using Western Lighting Chemiluminescent detection reagent (Perkin‐Elmer). 
For Figure 5, SecA1 was detected using an anti-SecA1 (1:10000) antibody, as previously 




(59). MspA was detected using anti-MspA (1:2000) antibody gifted from Dr. Michael 
Niederweis. GroEL2 was detected using an anti‐HIS (1:10000) (Abgent) antibody, as previously 
described (56).  
Subcellular fractionation 
Subcellular fractions were generated for Figure 5 as described previously (57). Briefly, 
M. smegmatis strains were grown in 50ml Mueller Hinton broth to an OD600nm of 1.0. Cells 
were pelleted for 10min at 3000xg and resuspended in 2.5ml 1X PBS buffer containing protease 
inhibitor cocktail used at 1:500 dilution. Cells were lysed by 3X passage through a French 
pressure cell. Unlysed cells were removed by centrifugation at 3000 x g for 30 min to generate 
clarified whole cell lysates (WCLs). The WCLs were spun at 27,000 x g for 30 min to pellet the 
cell wall fraction only (CW). The supernatant following CW isolation was spun at 100,000 x g 
for 2 hr to separate the membrane fraction (MEM) and collect the soluble cytoplasm-containing 
fraction (SOL). Fractions were separated by SDS-PAGE, and the total amount of CW, MEM, 
and SOL fractions shown are equivalent to the amount of WCL loaded.  
Site-directed mutagenesis of mce4E 
The cysteine at position 16 of Mce4E was changed to an alanine using site-directed 
mutagenesis to generate Mce4EC16A. The mce4E expression plasmid pLR106 was used as a 
template. The primer sequences used are listed in Supplemental Table 2.4. Dpn1 (NEB) was 
added to degrade the methylated template prior to transformation into E. coli. The mutation was 







M. smegmatis cells were transformed with plasmids either expressing HA fusion proteins 
or control plasmids. Strains were grown in 50ml Mueller Hinton broth to an OD600nm of 0.5. 
Cells were pelleted for 10min at 3000xg and resuspended in 2.5ml 1X PBS buffer containing 
protease inhibitor cocktail used at 1:500 dilution. Cells were lysed by 2X passage through a 
French pressure cell. Unlysed cells were removed by centrifugation at 3000 xg for 30 min to 
generate clarified whole cell lysates. Equal amounts of lysates (normalized by OD) or a total of 
1mg of protein for samples used for LC-MS/MS were diluted in 1ml of 1X PBS + protease 
inhibitors, to which 30l of anti-HA agarose (Sigma-Aldrich) was added and subsequently 
mixed end to end at 4C for 4hrs. The immunoprecipitations were next pelleted and washed 4X 
with 1ml 1X PBS + protease inhibitors. After the final wash, the agarose beads were resuspended 
in 25ul of 1X SDS-PAGE buffer, boiled, run on 15% SDS-PAGE gels, transferred onto 
nitrocellulose membranes and immunoblotted or were resuspended in 30ul of 1X PBS for LC-
MS/MS analysis. 
Immunoprecipitation and on bead LC-MS/MS 
Sample Preparation for LC-MS: Immunoprecipitated samples (prepared as described 
above; n=2) were subjected to on-bead trypsin digestion, as previously described (60). After the 
last wash buffer step, 50 µl of 50 mM ammonium bicarbonate (pH 8) containing 1 µg trypsin 
(Promega) was added to beads overnight at 37ºC with shaking. The next day, 500 ng of trypsin 
was added for an additional 3hrs at 37ºC with shaking. Supernatants from pelleted beads were 
transferred, then beads were washed twice with 50 ul LC/MS grade water. These rinses were 
combined with original supernatant, then acidified to 2% formic acid. Peptides were desalted 




LC-MS/MS Analysis: The peptide samples were analyzed by LC/MS/MS using an Easy 
nLC 1200 coupled to a QExactive HF mass spectrometer (Thermo Scientific). Samples were 
injected onto an Easy Spray PepMap C18 column (75 μm id × 25 cm, 2 μm particle size) 
(Thermo Scientific) and separated over a 120 min method. The gradient for separation consisted 
of 5–40% mobile phase B at a 250 nl/min flow rate, where mobile phase A was 0.1% formic acid 
in water and mobile phase B consisted of 0.1% formic acid in 80% ACN. The QExactive HF was 
operated in data-dependent mode where the 15 most intense precursors were selected for 
subsequent fragmentation. Resolution for the precursor scan (m/z 350–1600) was set to 120,000 
with a target value of 3 × 106 ions. MS/MS scans resolution was set to 15,000 with a target value 
of 5 × 104 ions, 60 ms max injection time. The normalized collision energy was set to 27% for 
HCD. Dynamic exclusion was set to 30 s, peptide match was set to preferred, and precursors 
with unknown charge or a charge state of 1 and ≥ 7 were excluded. 
Data Analysis: Raw data were processed using the MaxQuant software suite (version 
1.6.3.4) for identification and label-free quantitation (61). Data were searched against a Uniprot 
Mycobacterium smegmatis (strain ATCC 700084 / mc(2)155) database (containing 6602 entries) 
using the integrated Andromeda search engine. A maximum of two missed tryptic cleavages were 
allowed. The variable modification specified was oxidation of methionine and N-terminal 
acetylation. Label-free quantitation (LFQ) was enabled. Results were filtered to 1% FDR at the 
unique peptide level and grouped into proteins within MaxQuant (61). Perseus software (version 
1.6.14.0) was used for further processing. Only proteins with >1 unique+razor peptide were used 
for LFQ analysis. Proteins with >50% missing values were removed and missing values were 
replaced from normal distribution within Perseus. Log2 fold change ratios of the Mce4A-HA 




intensities and proteins with log2 fold change ≥1 were considered significant. Student’s t-test 
was performed and p-values were calculated; proteins with p-value<0.05 (ie, -log10 p-
value>1.33) were considered significant. All results can be found in Supplemental Data Set 1. 
The mass spectrometry proteomics data have been deposited to the ProteomeXchange 












Figure 2.1 Mce-domain containing operon organization 
A. Depiction of the mycobacterial mce4 operon and other genes associated with Mce4 
transporter function. “C” indicates the lipobox cysteine conserved within MceE proteins. Solid 
color genes are shared between Mycobacterium tuberculosis and Mycobacterium smegmatis. 
Hatched color genes are found only in Mycobacterium smegmatis. Genes located within a black 
box are outside of the mce4 locus. B. Depiction of the E. coli mla operon and other genes 








Figure 2.2 Domains of MCE-domain containing proteins 
A. Mycobacterial Mce proteins and B. E. coli Mla, YebT/LetB and PqiB proteins. The Mce 










Figure 2.3 Individual Mce4 proteins, Mam proteins, and OmamA and OmamB are required for 
M. smegmatis to grown on and take up cholesterol 
A-E. Growth of 104 colony forming units (cfu) of M. smegmatis strains with cholesterol as the 
sole carbon source was measured over time using resazurin reduction as a fluorescent readout of 
metabolic activity. Cholesterol growth curves measured by resazurin reduction of A. Δmce4A 
and complemented strains B. Δmce4E, Δmce4Epolar and complemented strains C. Δmam4Apolar 
and complemented strains D. ΔomamA, ΔomamB and complemented strains and E. ΔomamCD 
and ΔomamEF mutant M. smegmatis strains are depicted. F-G. Cholesterol uptake was measured 
by incubating M. smegmatis strains with 4-C14-cholesterol for three hours, and the cell 
associated radioactivity was measured using a scintillation counter. Measurements of cholesterol 
uptake were normalized as a percentage of the value of WT M. smegmatis set to 100%. All 
strains were complemented with multicopy (mc) or single copy (sc) plasmids as indicated. 
Mutant strains contain empty vectors (EV) as indicated. Error bars represent standard deviation. 
* indicates p<0.001 compared to WT. Results are representative of at least three independent 






Figure 2.4 Individual mce4, mam4, and omamA and omamB M. smegmatis mutants and 
complemented strains do not have a growth defect compared to WT when growing on glucose 
and glycerol carbon sources. 
A-E. Growth of 104 colony forming units (cfu) of M. smegmatis strains on glucose and glycerol 
as the sole carbon sources was measured over time using resazurin reduction as a fluorescent 
readout of metabolic activity (2, 3). Glucose and Glycerol growth curves measured by resazurin 
reduction of A. Δmce4A and complemented strains B. Δmce4E, Δmce4Epolar and complemented 
strains C. Δmam4Apolar and complemented strains D. ΔomamA, ΔomamB, and complemented 
strains E. ΔomamCD and ΔomamEF mutants and F. Δmce4E with Mce4EC16A complementation 






Figure 2.5 Localization of Mce4A and Mce4E proteins 
A. Immunoblots of Mce4A and B. Mce4E proteins show that Mce4A and Mce4E antibodies are 
specific and do not cross react with other Mce proteins. Arrow indicates Mce4A band to 
distinguish it from the higher species cross-reacting band. Mutant strains contain empty vectors 
(EV) as indicated. C. Localization of Mce4A and Mce4E protein in WT M. smegmatis. 
Subcellular fractions were isolated using ultracentrifugation, during which clarified whole cell 
lysate (WCL) was separated into cell wall (CW), membrane (MEM), and soluble (SOL) 
fractions. Fractions were separated by SDS-PAGE and were immunoblotted for Mce4A and 
Mce4E proteins. The total amount of CW, MEM, and SOL fractions shown is equivalent to the 
amount of WCL loaded. WCL from a M. smegmatis strain lacking all six Mce systems (Δ6X 




various fractions include the SecA1 ATPase (MEM and SOL) (6), the SecY translocation 
permease (MEM) (7), the MspA porin protein (CW and SOL) (8), and the GroEL chaperone 
protein (SOL) (8). Quantification of D. Mce4A and E. Mce4E proteins in subcellular fraction 
western blots using ImageJ software (9). * indicates p<0.001 and error bars indicate the standard 










Figure 2.6 Mce4A and Mce4E protein levels are reduced in the absence of individual Mce4, 
Mam4, OmamA, and OmamB proteins 
A. Protein levels of Mce4A and B. Mce4E were assessed in WT, mutant and complemented M. 
smegmatis strains via immunoblot. Arrow indicates Mce4A band to distinguish it from the higher 
species cross-reacting band. Mutant strains contain empty vectors (EV) as indicated. Protein 
levels of GroEL were assessed to ensure equal protein loading across strains. Results are 





Figure 2.7 Lipobox cysteine of Mce4E is not necessary for Mce4 transporter function 
A. Praline Multiple Sequence Alignment of Mycobacterium smegmatis MceE proteins with 
lipobox cysteines highlighted in green (63). B. Immunoblot confirming expression by mce4E 
complementation plasmids. C. Growth of 104 colony forming units (cfu) of M. smegmatis strains 
on cholesterol was measured using resazurin reduction as a fluorescent readout of metabolic 
activity. D. Radioactive cholesterol uptake was measured using a scintillation counter. 
Measurements of cholesterol uptake were normalized as a percentage of the value of WT M. 
smegmatis set to 100%. Error bars represent standard deviation. * indicates p<0.001 compared to 
WT. Results are representative of at least three independent experiments. E. Protein levels of 
Mce4A were assessed in WT, mutant and complemented M. smegmatis strains via immunoblot. 
Arrow indicates Mce4A band to distinguish it from the higher species cross-reacting band. 
GroEL levels were used as a loading control across strains. Mutant strains contain empty vectors 





Figure 2.8 Mce4A and Mce4E interact 
Clarified Whole Cell Lysate generated by passage through a French pressure cell was used for 
co-immunoprecipitation with anti-HA conjugated beads followed by immunoblot analysis. The 
amount of Clarified Whole Cell Lysate (Lys) loaded represents one-fifth of the amount of protein 




expressing either Mce4A-HAmc or Mce4Amc without a tag as a control. HA antibody was used to 
detect Mce4A-HA and Mce4E antibody was used to detect Mce4E in the co-immunoprecipitate. 
B. Strains used for immunoprecipitation were M. smegmatis Δmce4E expressing either Mce4E-
HAmc or Mce4Emc without a tag as a control. Mce4E antibody was used to detect Mce4E-HA and 
Mce4A antibody was used to detect Mce4A in the co-immunoprecipitate. Arrow indicates 
Mce4A band to distinguish it from the higher species cross-reacting band. MspA antibody was 
used to detect MspA as a negative control. C. Strains used for immunoprecipitation were M. 
smegmatis Δmce4A expressing either Mce4A-HAsc or WT expressing an empty vector (EV) HA 
tag. HA antibody was used to detect Mce4A-HA and Mce4E antibody was used to detect Mce4E 
in the co-immunoprecipitate. D. Strains used for immunoprecipitation were M. smegmatis 
Δmce4E expressing either Mce4E-HAsc or WT expressing an empty vector (EV) HA tag. HA 
antibody was used to detect Mce4E-HA and Mce4A antibody was used to detect Mce4A in the 
co-immunoprecipitate. Arrow indicates Mce4A band to distinguish it from the higher species 





Figure 2.9 Mce4A-HA and Mce4E-HA expression plasmids complement the mutant phenotypes 




A-E. Growth of 104 colony forming units (cfu) of M. smegmatis strains with cholesterol or 
glucose and glycerol as the sole carbon source(s) was measured over time using resazurin 
reduction as a fluorescent readout of metabolic activity (2). Cholesterol growth curves measured 
by resazurin reduction of A. Δmce4A and mce4A-HA multicopy expression strains C. Δmce4E 
and mce4E-HA multicopy expression strains E. Δmce4A and mce4A-HA single copy expression 
strains G. Δmce4E and mce4E-HA single copy expression strains of M. smegmatis strains are 
depicted. Glucose and Glycerol growth curves (cfu) of B. Δmce4A and mce4A-HA multicopy 
expression strains D. Δmce4E and mce4E-HA multicopy expression strains F. Δmce4A and 
mce4A-HA single copy expression strains H. Δmce4E and mce4E-HA single copy expression 












Figure 2.10 Label-free quantitation of proteins enriched in the Mce4A-HA immunoprecipitation 
Proteins identified by > two unique peptides in Mce4A-HA immunoprecipitation as compared to 
an HA only control are shown plotted by log2 (Mce4A-HA/control) and -log10(p value). 
Proteins with a p-value <0.05 and a minimum 2-fold enrichment (log2 = 1.0) in the Mce4A-HA 
immunoprecipitate compared to control were considered interactors (highlighted yellow 
quadrant). Mce4 transporter component proteins are marked on the plot with blue triangle 








Table 2.1 Percent identity between M. smegmatis Mce4 proteins determined with the NCBI 
BLAST Two-sequence Alignment function, using the BLOSUM62 matrix (66) 
 Mce4A Mce4B Mce4C Mce4D Mce4E Mce4F 
Mce4A 100 22.87 26.04 22.14 24.71 21.26 
Mce4B 22.87 100 21.68 23.02 18.97 24.18 
Mce4C 26.04 21.68 100 23.19 25.00 21.76 
Mce4D 22.14 23.02 23.19 100 21.13 22.73 
Mce4E 24.71 18.97 25.00 21.13 100 24.39 




















Source or reference 
mc2155 Wildtype (WT) Snapper et al., 1990 (67) 
Δmce4A ΔMSMEG_5900 This study 
Δmce4E ΔMSMEG_5896 This study 
Δmce4Epolar ΔMSMEG_5896 with polar 
effects that disrupt 
MSMEG_5895 
This study 
Δmam4Apolar ΔMSMEG_5894 with polar 
effects that disrupt 
MSMEG_5893 
This study 
ΔomamA ΔMSMEG_0235 Perkowski et al., 2016 (37) 
ΔomamB ΔMSMEG_0236 This study 
ΔomamCD ΔMSMEG_4771-4770 This study 
ΔomamEF ΔMSMEG_2864-2865 This study 
Δ6X mce Δmce1, Δmce3, Δmce4, 
Δmce5, Δmce5b, and Δmce7 















Table 2.3 Plasmids 
Plasmids Genotype and/or 
description 
Source or reference 
pMV261 Mycobacterial multicopy 
plasmid with hsp60 promoter; 
KanR 
Stover et al., 1991 (68) 
pLL2 Mycobacterial single copy 
plasmid that integrates at the 
tweety attB site; HygR 
Ligon et al., 2013 (58) 
pJSC77 pMV261 with a cloning site 
for generating HA tagged 
fusions; KanR 
Glickman et al., 2000 (69) 
pUC19 E. coli cloning vector; CarbR  New England Biolabs 
pCR2.1 - TOPO Cloning vector for topo 
cloning; AmpR and KanR  
Invitrogen 
pMP62 (also referred to as 
pYUB657) 
Allelic exchange suicide 
vector containing sacB 
counterselection marker; 
HygR 
Pavelka et al., 1999 (70) 
pMP1064 pBluescript KS res1-hyg-res1 
cassette flanked by SmaI sites  
Martinelli and Pavelka, 2016 
(71) 
pJV53 Mycobacterial multicopy 
plasmid encoding 
recombineering proteins gp60 
and gp61; KanR 
Van Kessel and Hatful, 2007 
(72) 
pMP854 Mycobacterial multicopy 
plasmid encoding resolvase; 
KanR 
Sanders AN et al., 2014 (73) 
pLR62; Δmce4A allelic 
exchange suicide vector 
pMP62 containing upstream 






pJSC77 containing mce4A Miller et al., 2019 (74) 
pLR101; P hsp60-mce4Ams 
multicopy  
pBM44 with HindIII site 
filled in by Klenow and self-
ligated at the HpaI site to 
remove the HA tag from 
mce4A. 
This study 
pLR111; P hsp60-mce4Ams-HA 
singlecopy 
mce4A-HA from pBM44 
cloned into pLL2 cut with 
NotI and EcoRV 
This study 
pLR112; Δmce4E precursor 
recombineering plasmid 
Upstream and downstream 





(MSMEG_5896) with an 
EcoRV site at the junction 
cloned into pUC19 cut with 




cassette from pMP1064 was 
cloned into pLR112 cutwith 
EcoRV  
This study 
pLR142; mce4E TOPO 
intermediate  
mce4E in PCR-2.1 TOPO 
vector 
This study 
pLR106; P hsp60-mce4Ems 
multicopy  
mce4E from pLR142 
(MSMEG_5896) cloned into 
pMV261 cut with EcoRI and 
HindIII restriction sites  
This study 
pLR93; P hsp60-mce4Ems-HA 
multicopy  
pJSC77 containing mce4E 
(MSMEG_5896) cloned into 
MscI and HindIII restriction 
sites 
This study 
pLR116; P hsp60-mce4Ems-HA 
singlecopy 
mce4E-HA from pLR93 
cloned into pLL2 cut with 






Site Directed Mutagenesis of 
pLR106 to construct mce4E 
C16A 
This study 
pMB250; Δmce4EF precursor 
recombineering plasmid 
Upstream and Downstream 
fragments of mce4E 
(MSMEG_5896) with an 
EcoRV site at the junction 
cloned into pUC19 cut with 





cassette from pMP1064 
cloned into pMB250 cut with 
EcoRV 
This study 
pLR110; P hsp60-mce4EFms 
multicopy  
pMV261 containing mce4EF 
(MSMEG_5896 and 
MSMEG_5895) cloned into 
MscI and HindIII restriction 
sites  
This study 
pLR96; Δmam4AB precursor 
recombineering plasmid 
Upstream and Downstream 
fragments of mam4A 
(MSMEG_5894) with an 
EcoRV site at the junction 
cloned into pUC19 cut with 








cassette from pMP1064 
cloned into pLR96 cut with 
EcoRV  
This study 
pLR143; mam4A TOPO 
intermediate 
mam4A in PCR2.1 TOPO 
vector 
This study 
pLR107; P hsp60-mam4Ams 
multicopy  
pMV261 containing mam4A 
(MSMEG_5894) from 
pLR143 cloned into pmv261 
cut with EcoRI and HindIII 
restriction sites 
This study 
pLR130; P hsp60-mam4Ams 
singlecopy  
mam4A from pLR107 cloned 
into pLL2 cut with NotI and 
EcoRV 
This study 
pLR126; P hsp60-mam4Bms 
multicopy  
pMV261 containing mam4B 
(MSMEG_5893) cloned into 
MscI and HindIII restriction 
sites  
This study 
pLR132; P hsp60-mam4Bms 
singlecopy 
mam4B from pLR126 cloned 
into pLL2 cut with NotI and 
EcoRV 
This study 
pLR124; P hsp60-mam4ABms 
multicopy  
pMV261 containing mam4AB 
(MSMEG_5894 and 
MSMEG_5893) cloned into 
MscI and HindIII restriction 
sites  
This study 
pEP139; P hsp60-omamAms 
multicopy  
pMV261 containing omamA 
(MSMEG_0235)  
Perkowski et al., 2016 (37) 
pLR128; ΔomamB precursor 
recombineering plasmid 
Upstream and Downstream 
fragments of omamB 
(MSMEG_0236) with an 
EcoRV site at the junction 
cloned into pUC19 cut with 





cassette from pMP1064 
cloned into pLR128 digested 
with EcoRV  
This study 
pLR141; P hsp60-omamBms 
multicopy  
pMV261 containing omamB 
(MSMEG_0236) cloned into 






Upstream and Downstream 
fragments of omamCD 
(MSMEG_4771-4770) with 





cloned into pUC19 cut with 




cassette from pMP1064 






Upstream and Downstream 
fragments of omamEF 
(MSMEG_2864-2865) with 
an hpaI site at the junction 
cloned into pUC19 cut with 





cassette from pMP1064 
cloned into pLR138 digested 























Sequence (5’-3’) Description 
Mce4A_UPflank_forward pLR62 ACTAGTATGATCG
GCGGCACTGTCG 
Amplification of flank 
Upstream of mce4A 
(MSMEG_5900) for 






Amplification of flank 
Downstream of mce4A 
(MSMEG_5900) for 









Amplification of flank 
Upstream of mce4E 
(MSMEG_5896) for 
cloning into pUC19 




Mce4E_DWNflank_forward pLR112  AGCGGCGGATAT
CAGGCCGCCGAC
CCGTTCAAGATC 
Amplification of flank 
Downstream of mce4E 
(MSMEG_5896) for 
cloning into pUC19 
(EcoRI, HindIII) 











cloning into PCR2.1 









cloning into pJSC77 





















Amplification of flank 
Upstream of mce4E 
(MSMEG_5896) for 
cloning into pUC19 




Mce4EF_DWNflank_forward pMB250  CAACATGGATAT
CCCGTAGATGATC
GACCGGCTGAC 
Amplification of flank 
Downstream of mce4E 
(MSMEG_5896) for 
cloning into pUC19 
(EcoRI, HindIII) 






















Amplification of flank 
Upstream of mam4A 
(MSMEG_5894) for 
cloning into pUC19 
(EcoRI, HindIII) 
Mam4AB_UPflank_reverse pLR96  TCAGTTGATATCG
ATGGTGTCCAGC
GGCTCACTGCT 
Mam4AB_DWNflank_forward pLR96  ACCATCGATATCA
ACTGATGCGCTCC
AAGCTCGTC 
Amplification of flank 
Downstream of mam4A 
(MSMEG_5894) for 
cloning into pUC19 
(EcoRI, HindIII) 















cloning into PCR2.1 










cloning into pmv261 






















Amplification of flank 
Upstream of omamB 
(MSMEG_0236) for 
cloning into pUC19 








Amplification of flank 
Downstream of omamB 
(MSMEG_0236) for 
cloning into pUC19 











cloning into pmv261 











Amplification of flank 
Upstream of omamC 
(MSMEG_4771) for 
cloning into pUC19 












cloning into pUC19 
(EcoRI-HindIII) 








Amplification of flank 
Upstream of omamE 
(MSMEG_2864) for 
cloning into pUC19 








Amplification of flank 
Downstream of omamF 
(MSMEG_2865) for 
cloning into pUC19 
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CHAPTER 3: DISCUSSION 
Mycobacterium tuberculosis (Mtb) is estimated to have infected one-quarter of the 
world’s population, causing the disease tuberculosis (TB) in roughly 10 million people per year 
(1). With the rise of antimicrobial resistant Mtb strains there is a desperate need for new drugs to 
treat TB (1). Identification of novel drug targets marks the beginning of the drug discovery 
pipeline. The most common strategy for selecting drug targets is to focus on bacterial gene 
products involved in pathways that are essential for bacterial growth or survival; however, 
targeting such essential processes creates immense selective pressure for resistance mutations. 
The rise of antimicrobial resistance, an extreme of which is exemplified by totally drug resistant 
(TDR)-Mtb (2), is a tremendous threat to human health (3).  
The desperate need for new and novel drugs has led researchers to consider bacterial gene 
products involved in virulence pathways (virulence factors) as alternative drug targets. 
Antibiotics that target virulence pathways would act by decreasing bacterial pathogenesis and 
allowing the immune system to better clear infection (4–6). Potential benefits of targeting 
virulence pathways include the ability to limit disease progression in an environment that has 
less selective pressure for resistance mutations and with minimum perturbations to healthy 
microbiota. Limitations of anti-virulence drugs include that these drugs would be very specific to 
bacterial species (drug targets would be specific to the microbe), would not directly clear an 
infection, which poses the question of how the infection will proceed once the drug has been 




virulence drugs would most likely be administered in conjunction with, or as adjuncts to 
traditional antibiotics (4–6). Currently, there are five anti-virulence drugs approved by the Food 
and Drug Administration (FDA). All five of these approved, anti-virulence drugs are antibodies 
that bind to toxins and thereby block the function of toxins produced by produced by Clostridium 
botulinum, Clostridium difficile, and Bacillus anthracis (4–6). Toxins are a unique and ideal 
target for anti-virulence drugs because the target (the toxin) is accessible to the drug (the 
antibody) outside of the pathogen; therefore, there is no selective pressure put forth by the drug 
onto the pathogen to gather resistance mutations. 
Lipids are important for Mtb virulence (7–9). Mtb utilizes host lipids as an energy source 
(10–12) and as precursors for lipid biogenesis during infection (8, 13, 14). In addition, Mtb has 
an extensive array of unique cell envelope lipids, many of which elicit host immune responses 
crucial to disease progression. Therefore, lipid utilization or biogenesis pathways in Mtb could 
be anti-virulence drug targets. As proof of principle of lipids serving as anti-virulence targets, 
monoclonal antibodies that target the mycobacterial glycolipids lipomannan (LM) and 
lipoarabinomannan (LAM), which are surface lipids that bind to the macrophage mannose 
receptor and promote macrophage uptake (15), increase survival time and decrease bacterial 
burden in the lungs of Mtb infected BALB/c mice when supplied intravenously at the same time 
of Mtb infection (16). We believe that mycobacterial lipid import could be an additional anti-
virulence approach to targeting lipids. My work focused on characterizing the Mce transporter, a 
system for lipid uptake in mycobacteria that is linked to virulence, with the long-term goal of 




Mce transporters are lipid importers of mycobacteria 
Mce proteins were first discovered in mycobacteria for their ability to promote bacterial 
uptake by mammalian cells when produced heterologously in E. coli. These proteins were 
subsequently named Mammalian cell entry (Mce) proteins (17). Mce proteins, contain an MCE 
domain (pfam02470) that is found exclusively in proteins found in organisms or organelles with 
diderm structures, including many Gram-negative bacteria, mycobacteria, and eukaryotic 
chloroplast membranes (18, 19). While the role of mycobacterial Mce proteins in host cell 
invasion is still unclear, all the MCE domain containing proteins, so far, have been shown to play 
roles in lipid transport (19–28). In accordance, a growing body of knowledge supports 
mycobacterial Mce transporters being lipid importers. Different species of mycobacteria contain 
different numbers of mce operons, which may reflect their environmental niche. For instance, the 
soil dwelling mycobacteria Mycobacterium vanbaalenii and Mycobacterium smegmatis have 
respectively 11 and six mce loci. Bycontrast, the human-adapted and reduced genome of 
Mycobacterium leprae contains only one mce locus (mce1). Mtb encodes four Mce transporters 
(Mce1-4) (19). The Mce4 system imports cholesterol and Mce1 imports the fatty acids palmitic 
and oleic acid (12, 25–28). It is thought that the other Mce systems of Mtb (Mce2, Mce3) also 
function in lipid uptake although their substrates remain unknown.  
Mce transporters as potential anti-virulence drug targets 
Each Mce transporter of Mtb has been implicated in Mtb virulence (28–34); therefore, 
Mce transporters are plausible candidates for anti-virulence drugs. Mutations in mce1, mce2, 
mce3, and mce4 have been shown to cause an attenuated Mtb infection in mice (28, 31–35). 
During murine infection, Mtb replicates exponentially inside macrophages (acute growth phase) 




to an adaptive immune response (persistence phase) (36). Mtb Δmce1 mutants have a defect in 
the acute growth phase of murine infection (32), and Δmce4 have defect in persistent phase of a 
murine infection model (35). The Mce4 transporter imports cholesterol (12, 26–28). Cholesterol 
is present in the granulomas of late-stage TB (37), which correlates to Δmce4 mutant attenuation 
during persistence in a mouse. Of note, Δmce1 mutants have also caused hypervirulent 
phenotypes in mice in some studies, which remains to be clarified (29–31). The roles for 
different Mce systems in different phases of infection suggests that there may be a correlation 
between lipid sources and disease progression. An attractive target for an anti-virulence drug 
would be a Mce transporter component that affects multiple Mtb Mce transporters and thereby 
impact multiple stages of disease. However, to identify appropriate targets of Mce transporters 
will require a better understanding of Mce transporter structure and mechanism.  
The Mce4 transporter is a large, multi-protein cell envelope complex 
How lipids travel between the inner (IM) and outer (OM) membranes of diderm 
structures, including the cell envelope of mycobacteria, is a significant question as lipid transport 
is important for bacterial physiology. In addition, it is also a mechanistically interesting question 
because hydrophobic lipids cannot travel unassisted through a hydrophilic periplasm (38, 39). 
While the mechanism of lipid transport in mycobacteria is relatively unknown (14, 40), lipid 
transport between the IM and OM of E. coli is more thoroughly characterized and provides 
insight into how lipids may be traveling through the mycobacterial cell envelope (39, 41). The 
OM of E. coli consists of three major lipid or lipidated species: LPS, lipoproteins, and 
phospholipids. LPS is transported across the periplasm by the Lpt transporter. The Lpt 
transporter is an ABC transporter that uses energy from ATP hydrolysis to power the movement 




proteins (42, 43). Lipoproteins are transported across the periplasm via the Lol transport system. 
The Lol system uses a periplasmic chaperone, LolA, to transport lipoproteins from the IM 
LolCDE ABC transporter complex to the OM protein LolB (44). Finally, while the direction of 
transport remains unclear, the Mla transport system, which is another ABC transporter system, 
traffics phospholipids between the IM and OM of E. coli (45). Similar to the Lol system, the Mla 
transporter relies on a periplasmic chaperone protein, MlaC (46, 47), to transport phospholipids 
between the IM MlaBDEF complex (20) and the OM MlaA/OmpCF complex (47, 48). The 
periplasmic MlaD protein is a central component of the transport system as it forms a homo-
hexameric pore at the inner membrane. Lipids can bind to the center of the MlaD pore, which is 
thought to be the mechanism for protecting and directing lipids during transport in the cell 
envelope (20, 21, 49). The MlaD protein has a transmembrane (TM) domain at its N terminus, 
followed by an MCE-domain (pfam02470) at its C-terminus. E. coli encodes two other proteins 
with MCE domains, YebT/LetB and PqiB, which are two proteins that can also bind to 
phospholipids and function in lipid transport (21–24, 49). Interestingly, the Lpt, Lol, and Mla 
transporters are all complex ABC transporters with additional proteins that connect IM and OM 
complexes. 
Mce transporters import lipids through the cell envelope of mycobacteria; however, while 
the components that contribute to Mce transport have been identified, the mechanism of Mce 
transport is unknown. Initial clues to the mechanism of Mce transport came from the genomic 
organization of mce operons. Each mce operon encodes two predicted membrane permeases, 
YrbEA and YrbEB, and six predicted solute binding proteins (SPBs), MceA-F. An unlinked 
ATPase, MceG, is predicted to act as an ATPase for all four Mce systems. In silico analysis of 




ABC transporter family because they encode a variation (EExDA) of the highly conserved EAA 
motif that binds to the ABC transporter cognate ATPase (19). Similarly, MceG also contains 
signatures of ABC transporter ATPases, including Walker A and B motifs as well as the LSGGQ 
motif (19). Therefore, early on, Mce transporters were predicted to be analogous to ABC 
transporters. However, Mce transporters are more complex than ABC transporters because 
within the operon there are six predicted SBPs, MceA-F, and linked to nearly all mce operons are 
genes that encode Mce Associated Membrane (Mam) proteins. Additionally, bioinformatics 
analyses identified five Orphaned Mce Associated Membrane (Omam) proteins in Mtb, which 
share predicted structural similarity to Mam proteins but are not encoded by genes linked to mce 
operons (19, 50).  
The work described in this thesis demonstrated that Mce4A,E,F, Mam4A,B, and 
OmamA,B are required for growth on cholesterol and cholesterol uptake in the model 
mycobacterium, M. smegmatis.  These results complement the report from García-Fernández et 
al., which demonstrates that every gene in the mce4 locus (yrbE4A,B, mce4A-F, mam4A,B) is 
required for mycobacterial growth on cholesterol. However, in that study only Mce4A was 
specifically evaluated and shown to be required for cholesterol uptake (51). Cholesterol uptake 
experiments directly reflect a role in Mce4 lipid import, whereas growth on cholesterol 
experiments also include events downstream of lipid import (i.e., metabolism). Additional 
proteins that have been identified as contributing to cholesterol uptake by mycobacteria are 
LucA and MceG. LucA was identified in a screen conducted in Mtb for genes involved in fatty 
acid uptake (metabolism). LucA was subsequently demonstrated through lipid uptake 
experiments to contribute to both Mce1 and Mce4 transporter functions (25). MceG, the ATPase, 




later shown through lipid uptake experiments to be required for Mce1 and Mce4 function (52, 
53). Interestingly, MceG, LucA, OmamA, and OmamB are encoded by genes that are localized 
distant to mce loci and all have been shown to contribute to both Mce1 and Mce4 transporter 
systems. We speculate that these four proteins have roles in all of the Mce transporter systems of 
mycobacteria (25, 35, 50, 52, 53). OmamA, OmamB, and LucA are proposed to play roles in 
stabilizing Mce transporters. It is possible that OmamA, OmamB, and LucA form stabilizing 
scaffolds that work with the various Mce transporters (25, 50).  
We hypothesized that Mce transporters are large, multi-protein complexes within the 
mycobacterial cell envelope; and a goal of my thesis research was to determine interactions 
between Mce transporter components. As a model of experiments to study protein interactions 
within a large complex, we referred to the characterization of the VirB Type IV Secretion 
System (T4SS), which is a large, multiprotein transporter complex in the Gram-negative cell 
envelope. T4SSs of Gram-negative bacteria translocate macromolecules from the bacterial 
cytoplasm across both the IM and OM and into a target cell (54–56). The VirB T4SS of 
Agrobacterium tumefaciens, a plant pathogen, translocates virulence factors into host cells. The 
VirB machinery consists of 12 different proteins, VirB1-11 and VirD4, that multimerize and 
assemble to form a transenvelope complex (54–56).  
The VirB machinery was initially studied by mutational analysis, protein stability, and 
protein-protein studies. When deleting specific alleles of the virB operon, multiple studies report 
that the protein levels of other virB encoded components decreased. This co-dependence of VirB 
protein levels on one another suggests that these components are in complex together and that 
they are unstable (degraded) in the absence of their normal interacting partners (57, 58). For 




VirB11 are decreased (57). Direct protein-protein interactions between VirB components were 
established by protein-fragment complementation and biochemical assays with purified proteins 
(59–62). For example, VirB8 was found to interact with VirB1, VirB4, VirB8, VirB9, VirB10, 
VirB11 by yeast-two hybrid experiments and these interactions were confirmed with purified 
recombinant proteins (59, 60), which additionally detected an interaction between VirB8 and 
VirB5 (61, 62). Multiprotein VirB subcomplexes were assessed by BN-PAGE and gel filtration 
techniques, in which membrane complexes are solubilized, separated, and components identified. 
Overall, two complexes were identified using these techniques (61, 63). A low molecular weight 
complex which included the T-pilus subunits, VirB2 and VirB5, and a high molecular weight 
complex that was proposed to contain the translocation channel complex, included VirB6, 
VirB7, VirB8, VirB9, and VirB10 (63). Further studies that changed the membrane 
solubilization stringency with different levels of detergent revealed that VirB6, 7, and 8 could 
also associate with the low molecular weight T-pilus complex, and these proteins (VirB6, 7, and 
8) were proposed to connect the two complexes (61). A third functional group of VirB T4SS 
proteins include the cytoplasmic ATPases, VirB4, VirB11, and VirD4, which drive complex 
assembly and energize the system to translocate substrates. Additionally, VirB3 binds to and 
functions with VirB4 (64) and VirB1 is a lytic transglycosylase that modifies the cell wall 
peptidoglycan to allow assembly of the T4SS (65). These studies defining the VirB/VirD4 
complex were later confirmed and expanded upon with the use of X-ray crystallography and 
cyrogenic electron microscopy (Cryo-EM) (technique discussed below).  
VirB8 is therefore essential to VirB assembly and function. VirB8 is required for 
stabilization of VirB1, VirB1, VirB3, VirB4, VirB5, VirB6, VirB7, and VirB11 (57) and VirB8 




substrate, T-DNA (66). Such detailed understanding of the VirB T4SS has led to anti-virulence 
inhibitor campaigns that target VirB8 (67, 68). Interestingly, Mam and Omam proteins of Mce 
transporters share predicted structural similarity to VirB8 (50, 69). We speculate that Mams and 
OmamA and OmamB may play a similar role to VirB8 in stabilizing Mce transporters, and may 
be candidates for anti-virulence drug targets. Our goal is to provide the same level of 
understanding of Mce systems to enable rational design or screening of anti-virulence 
compounds that inhibit Mce transporters.  
In our studies of the Mce4 transporter complex, we show that when missing Mce4E, 
Mce4F, Mam4A, Mam4B, OmamA, or OmamB proteins, the levels of Mce4A and Mce4E 
proteins decreased compared to WT M. smegmatis or complemented strains. These findings are 
reminiscent of the studies with VirB proteins and they are consistent with Mce4A and Mce4E 
being in a complex with other Mce, Mam, and Omam proteins. In further support of Mce 
components existing in a complex together, we demonstrate through co-immunoprecipitation 
experiments that Mce4A and Mce4E interact. To expand upon the Mce4A-Mce4E interaction 
revealed by the Mce4A co-immunoprecipitation, we used IP-MS to discover additional proteins 
associating with Mce4A-HA. We expected the IP-MS analysis to demonstrate interactions 
among additional Mce4 transporter components and to potentially reveal new and unpredicted 
interaction partners. We identified 82 proteins as significantly enriched in our Mce4A-HA IP-
MS in comparison to the HA-only control. Excitingly, we identified every single mce4 locus-
encoded component (YrbE4A,B, Mce4A-F, Mam4A,B) as well as OmamA and OmamB and the 
cytoplasmic ATPase, MceG. Mce1 transporter components were also identified in the IP-MS 
analysis, which suggests cross-talk between the Mce1 and Mce4 systems. However, the 




the conditions employed in our mutant analysis, there was no indication that Mce1 components 
can compensate for loss of the specific Mce4 or Mam4 proteins we investigated. Other proteins 
of interest identified are the 19 proteins besides the Mce4 and Mce1 transporter components, that 
share homologs in Mtb because Mtb also encodes a functional Mce4 transporter. 18 of these 
proteins have been detected in membrane or cell wall fractions of Mtb (70, 71) and the 19th 
protein is predicted to have a TM domain by the TMHMM program (72), which supports these 
proteins localizing to the cell envelope compartment similar to Mce4 transporters components 
with the exception of MceG. 
In parallel with the Mce4A-HA IP-MS, we performed IP-MS to identify proteins that co-
immunoprecipitated with Mce4E-HA IP. Multiple comparison analysis using Analysis of 
Variance (ANOVA) of the LFQ data for the proteins associated with the Mce4A-HA, Mce4E-
HA, and HA-alone control IPs identified 104 proteins (44 with Mtb homologs) as significantly 
enriched (q-value <0.05 and a minimum 2-fold enrichment (log2 = 1.0)) in either the Mce4A-HA 
and/or Mce4E-HA IP as compared to the HA-only control (APPENDIX II). 43 proteins, 
including all the Mce4A-F proteins were identified as significantly enriched in both Mce4A-HA 
and Mce4E-HA IPs compared to the HA-only control. Two additionally interesting proteins in 
this group enriched in both Mce4A-HA and Mce4E-HA IPs are the predicted lipoprotein LprE 
(MSMEG5043/Rv1252c) and the protein encoded by MSMEG4268/Rv2200c, an 
uncharacterized protein of unknown function that was among the top five most enriched proteins 
in either IP-MS analysis. Both of these proteins share Mtb homologs that have either been shown 
experimentally or are predicted to be exported. There were 27 proteins that were identified as 
interactors in the Mce4A-HA IP that were not identified as significant interactors in the Mce4E-




(YrbE4A,B, Mam4A,B, OmamA,B and the ATPase (MceG). The absence of these additional 
Mce transporter proteins from the Mce4E-HA IP-MS analysis suggests that Mce4A interacts at 
the IM with a subcomplex of predicted IM proteins (YrbE4A,B, Mam4A,B, and OmamA,B) as 
well as the cytoplasmic ATPase, MceG, whereas Mce4E does not.  Perhaps, Mce4A connects 
this IM subcomplex to a heterohexameric complex of Mce4A-F proteins. 33 proteins were 
identified as interactors of Mce4E-HA IP but not Mce4A-HA.  Some of the interesting proteins 
in this category are MSMEG4254/Rv2187, MmpL5 (MSMEG1382/Rv0676c), and Wag31 
(MSMEG4217/Rv2145c). MSMEG4254/Rv2187 encodes a protein that has been experimentally 
identified to be in the mycobacterial cell wall and membrane fractions (70, 71) and is predicted 
to be involved in lipid metabolism (73). An interaction between Mce4E and the MSMEG4254-
encoded protein is interesting because it would connect the functions of lipid transport and lipid 
metabolism. MmpL proteins are integral membrane transporter proteins that generally 
translocate lipids from the cytoplasm to the cell wall. However, MmpL5 is currently understood 
to be a siderophore transporter (74). Finally, Wag31 is involved in regulating peptidoglycan 
synthesis at the cell poles of mycobacteria, suggesting that Wag31 may play a role in modifying 
the cell envelope, which would be a necessary step to build Mce transporters in the cell wall (75, 
76). Overall, potential interactors significantly identified in the Mce4A-HA and Mce4E-HA IP-
MS analyses that had no prior association with Mce transporters will need to be further 
characterized and validated; however, they represent exciting and compelling proteins that may 
contribute to Mce4 function. The results from our IP-MS experiments have revealed a potential 
for Mce4A and Mce4E to have different interaction partners within the Mce4 transporter system, 




transporters, which are exciting possibilities that could expand our understanding of Mce 
transport systems.  
Identifying direct Protein-Protein Interactions by protein-fragment complementation assays 
(PCA). 
Proteins identified from co-immunoprecipitation experiments are not necessarily in 
direct, physical interaction with one another, but rather may be indirectly interacting in complex 
together. A common technique to identify direct protein-protein interactions is the use of protein-
fragment complementation assays (PCA) (77–80). PCA assays function to identify protein-
protein interactions by fusing two proteins of interest to respective halves of a reporter protein 
that is split into two domains. If the two proteins of interest interact, the reporter protein is 
reconstituted and regains function, leading to a detectable, assayable readout. Yeast two-hybrid 
(Y2H) is a PCA that was used to determine protein-protein interactions between VirB T4SS 
components (59). Y2H uses the yeast Gal4 transcription factor as the reporter protein and the test 
of interactions is performed in yeast, which is a eukaryote. While Y2H is very powerful, it 
utilizes a eukaryotic transcription factor and eukaryotic host cell, which has limitations for 
studying bacterial protein interactions. The protein interactions will need to take place in the 
yeast nucleus and bacterial genes may struggle to express in the eukaryotic environment. 
Additionally, there could be problems with bacterial protein localization, folding, stability, and 
post-translational modifications in the eukaryotic system (80, 81).  
 PCA systems that utilize bacterial hosts have also been developed (77, 78, 80). A 
common bacterial two-hybrid (BTH) assay uses the reporter adenylate cyclase (AC) from 
Bordetella pertussis in E. coli. Bacterial AC Two Hybrid (BACTH) detects protein-protein 




two halves of AC are named T18 and T25. If two AC fusion proteins interact, AC activity will be 
restored, converting ATP into cyclic AMP (cAMP). cAMP will go on to bind to catabolite 
activator protein, CAP, a transcription factor. When bound to cAMP, the binding affinity of CAP  
for its cognate promoters increases leading to increased transcription of the lactose and maltose 
catabolic operons. When sets of AC fusion proteins are produced in E. coli strain 
BTH101(Figure 3.1A), the bacteria appear dark purple/pink on MacConkey maltose plates if 
there is a positive interaction between the AC-fusion constructs.  An interaction can also be 
detected as blue colonies on X-Gal plates. As a quantitative readout, a beta-galactosidase assay 
can be performed in which the beta-galactosidase substrate, ONPG, is added to permeabilized 
liquid cultures of the BTH101 transformants. The enzymatic reaction of beta-galactosidase 
cleaving ONPG can be read as on OD420 absorbance, normalized to the starting cell density, and 
reported as a Miller Unit (79). Benefits of BACTH include that with E. coli as the host, the 
system is quick and easy to use. Disadvantages for studying interactions using BACTH include 
that fusions to T18 or T25 AC halves may result in the mis-folding, protein instability, or 
physically prevent interactions of the fused proteins (79). Additionally, a problem of studying 
interactions between mycobacterial proteins using BACTH include that E. coli is still a 
heterologous host. Finally, for multi-protein systems such as the Mce transporter, protein-protein 
interactions may not occur if other components of the system are not in place.  
Using BACTH, we tested for interactions between full length Mtb OmamA with itself 
and with the full-length Mtb OmamB, both of these proteins were identified as co-
immunoprecipitating with Mce4A by our MS analysis. As is the case for OmamA and OmamB, 
Omam and Mam proteins are often encoded in genomic pairs (19, 50). Using BACTH in E. coli, 




because Omam and Mam proteins are integral membrane proteins with TM domains we worried 
about the possibility that this was a false positive result. Testing for protein-protein interactions 
between membrane proteins using BTH assays can lead to higher false-positive interactions 
compared to soluble proteins because overproducing membrane proteins with the BACTH 
system increases their local concentration and can result in overcrowding in the membrane (79, 
82–85). To address this possibility, we tested our full length OmamA and OmamB-AC fusions 
for their ability to interact with the E. coli MalF, the inner membrane maltose permease protein 
in the BACTH system. This use of MalF to demonstrate non-specific interactions between 
integral membrane proteins was previously employed with PspB, a membrane phage shock 
protein from Yersina enterocolitica, as MalF and PspB should not naturally interact as MalF is 
not found in Y. enterocolitica (82). In our experiments, we found the Mtb Omams and MalF 
proteins interacted (Figure 3.1C). This outcome raised doubt about the biological significance of 
the interactions we initially observed between full-length OmamA and OmamB (Figure 3.1B).  
 In order to avoid the issue of TM domains promoting nonspecific interactions in the 
BACTH system, we next cloned the periplasmic domains (missing the TM domain) of Mtb 
OmamA and OmamB N-terminally fused to the T18 or T25 (Figure 3.1D). These soluble, 
periplasmic domains of Mtb OmamA and OmamB, referred to as OmamAp and OmamBp, were 
still able to interact with themselves and each other in the BACTH assay (Figure 3.1E). Most 
importantly, Mtb OmamAp and OmamBp did not interact with the MalF membrane specificity 
control (Figure 3.1F). Because our other experiments investigating Mce transporters were done 
in M. smegmatis, we next wanted to repeat BACTH using the M. smegmatis OmamA and 
OmamB proteins. We cloned soluble, periplasmic domains M. smegmatis OmamA (OmamAp) 




we observed that M. smegmatis OmamCp and OmamDp, another genomic omam pair, interact 
(Figure 3.1D, Figure 3.1H), M. smegmatis OmamAp and OmamBp were not observed to interact 
in the BACTH system (Figure 3.1G). M. smegmatis and Mtb OmamA proteins share 50% 
identify and 70% similarity and M. smegmatis and Mtb OmamB proteins share 59% identify and 
74% similarity (86). We are currently unsure why M. smegmatis OmamA and OmamB did not 
interact via BACTH.  
We also attempt use the BACTH system to study interactions involving Mtb Mce 
proteins; however, we had problems with Mce-AC fusion protein stability in E. coli as we could 
not detect Mce-AC fusion proteins via western blot. These protein stability issues may be due to 
the AC fusion preventing proper folding of the Mce proteins, or perhaps multiple Mce 
transporter components need to be expressed for individual Mce proteins to be stable. Overall, 
because BACTH is used in E. coli, BACTH may not be the best approach for studying 
interactions within multi-protein cell wall localized transporters that may require other 
transporter components to stably assemble or function properly. 
Another PCA system that can be utilized in bacteria uses split murine dihydrofolate 
reductase (DHFR) protein as the reporter (87). DHFR regulates cellular levels of 
tetrahydrofolate, whose derivatives are required for purine and thymidylate synthesis and DHFR 
is essential for all organisms. The antibiotic, trimethoprim (TRM), is an inhibitor of DHFR. 
However, bacterial DHFR is more susceptible to TRM than murine DHFR (mDHFR). mDHFR 
is split into the two non-functional, domains F1,2 and F3, and when these two domains are 
brought into close enough contact, mDHFR activity is reconstituted. Bacteria can be grown in 
the presence of a TRM at a concentration that effects bacterial DHFR but not mDHR, and only 




TRM resistance (87). An advantage for the mDHFR system is that it can be used in mycobacteria 
(25, 88).  
Nazarova et al (2017) use mDHFR PCA to investigate interactions with Mtb LucA, 
which is a predicted integral membrane protein with multiple TM domains. Protein levels of 
Mce1A, Mce1D, Mce1E, and MceG are down in a ΔlucA stain, which suggests that LucA plays a 
role in assembling or stabilizing Mce protein complexes. Interactors of LucA were identified 
using mDHFR two-hybrid, where Mtb LucA was fused to the F3 domain of mDHFR and co-
expressed in M. smegmatis with a library (2x10^6) of random Mtb protein fragments fused to the 
F1,2 domain of mDHFR. Four sibling clones were identified in this screen as being able to confer 
TRM resistance to M. smegmatis; all four of these clones contained an in-frame N terminal 
fragment of Mam4B (TM amino acids (aa) 1-75). Nazarova et al (2017) subsequently cloned 
only the N-terminal TM domain of Mam4B (amino acids 1-30) as a fusion to F1,2 mDHFR and 
showed that this single TM domain of Mam4B is sufficient to interact with LucA-F3 mDHFR. 
Because LucA affects the function of Mce1 and Mce4 transport, Nazarova et al (2017) also 
tested for interactions of F3-LucA with TM domains of Mam1A (TM aa 1-84), Mam1C (TM aa 
1-50), Mam1D (TM aa 1-103), or OmamA (TM aa 1-66) proteins fused to F1,2 mDHFR. They 
showed that LucA could interact with both full length and TM domains of Mam1C and OmamA, 
but not Mam1A or Mam1D. From their results, Nazarova et al (2017) speculate that LucA is 
recruited to stabilize Mce1 and Mce4 complexes by interacting with select Mam and Omam 
proteins (25). Given that the interactions were narrowed down to a 30 amino acid TM domain of 
LucA, it is worth noting that Nazarova et al (2017) did not perform controls to rule out non-
specific interactions between membrane proteins as we refer to above. It is also worth noting that 




Mce4 system that we did not identify in our Mce4A-HA IP-MS analysis. It is possible that LucA 
has a more transient interaction with Mce proteins, perhaps in regulation or assembly of the 
transporter, or that it has a more specific role with Omam and Mam proteins.  
 As an alternative to assaying for direct protein-protein interactions in vivo with PCA 
systems, in vitro techniques could also be used to test for interactions among purified Mce 
transporter components. A disadvantage to in vitro protein-protein interaction techniques is that 
the proteins of interest are removed from their native environment. If interactions in this system 
require extensive network of protein interactions it may be hard to map out specific, binary 
interactions in vitro. There has been very little study of purified Mce transporter components. So 
far, only Mce4A has been purified, and has been shown in binding affinity studies to interact 
with cholesterol-like lipids and has not yet been used to identify other protein binding partners 
(89). 
Determining the composition of Mce transporter complexes 
 In addition to mapping out direct protein-protein interactions, another future goal for 
characterizing Mce transporters would be to determine the size and complexity of these large, 
multi-protein systems. These approaches are complementary to the identification of direct 
protein-protein interactions in providing a complete picture of the Mce transporter complex. 
Additionally, these techniques can reveal whether all the components identified in functioning in 
Mce transport exist as one massive complex or makeup subcomplexes that assemble together, 
such as been described for VirB T4SS. Our experiments showing that proteins levels of Mce4A 
and Mce4E decrease when other Mce transporter component are missing, suggests that protein-




that investigate protein components occurring within complexes include non-denaturing Blue 
Native PAGE and Cryo-electron microscopy.  
Non-denaturing Blue Native PAGE and gel filtration 
Non-denaturing Blue Native (BN) PAGE is a method that can be applied to studying 
bacterial membrane protein complexes in their native conformation (90–92). During BN-PAGE, 
biological membranes are solubilized with detergents and subsequently mixed with the anionic 
dye, Coomassie blue G-250. The detergent is important to solubilize complexes from membranes 
while preserving complex structure. Common non-ionic detergents used in BN-PAGE are 
digitionin (0.5 to 1%), Triton X-100 (0.1 to 0.5%), Brij (0.1 to 0.5%), or dodecylmaltoside (0.1 
to 0.5%) (90). The Coomassie blue G-250 is soluble in water but will also bind to membrane 
proteins because of its hydrophobic properties. As a result, this dye causes proteins and 
complexes coated with it to become water soluble and acquire a negative charge (90–92). These 
dye-coated proteins and complexes are then separated according to size, shape, and charge using 
native acrylamide gradient gels. Protein complexes can then be immunoblotted with available 
antibodies to determine which proteins are within the complex or analyzed by LC/MS/MS as a 
non-biased approach to identify proteins within a complex. Alternatively, identified complexes 
can be run in a second-dimension gel, either denaturing or native, to determine individual 
proteins or sub-assemblies within protein complexes (90–92). Similar to BN-PAGE, membrane 
complexes can be solubilized with detergents and then run over a size exclusion column (SEC). 
The fractions of interest collected by SEC can then be analyzed to determine the identity of 
eluted proteins (93).   
BN-PAGE was first used to identify large (10kDa to 10MDa) protein complexes in the 




and protein-protein interactions of the VirB T4SS (61, 63). For example, in one study, Krall et al 
(2002) used BN-PAGE and probed for complexes containing VirB7, identifying two different 
membrane complexes containing VirB7 following extraction with the mild detergent dodecyl-β-
D-maltoside at 2% weight/volume (w/v) (63). The lower molecular weight complex, which 
migrated at 100 kDa, was revealed to contain the major T-pilus component VirB2 as well as 
VirB5 and VirB7. A second complex that ran on the native gel at a mass higher than 230 kDa 
included protein components of the translocation channel complex: VirB7, VirB8, VirB9, and 
VirB10. It is hypothesized that these subcomplexes are processed and assembled independent of 
one another. These studies were confirmed by gel filtration (63). A follow up study by Yuan et al 
(2005), subsequently confirmed the high and low molecular weight complexes Krall et al. (2002) 
identified by BN-PAGE (61). However, in contrast to Krall et al (2002), Yuan et al (2005) used 
detergent (0.03 % dodecyl-β-D-maltoside) while performing gel filtration and found that VirB6 
and VirB8 are additionally present in both fractions, suggesting that VirB6, VirB7, and VirB9 
may link the translocation channel to the Pilus subunits (61). These approaches could be very 
powerful for understanding Mce transporter complexes and potential subcomplexes. One can 
hypothesize that proteins encoded by the mce locus components (Yrbs, Mces, and Mams) may 
form a translocation channel complex whereas other Mce transporter components encoded in 
locations unliked to mce loci but have been shown to function and interact with different Mce 
transporters, such as the ATPase, MceG, as well as OmamA, OmamB, and LucA, form a 
separate stabilizing complex that can move between Mce transport systems. It is also possible 
that the translocation channel (hypothesized Mce proteins) and stabilizing proteins (hypothesized 
OmamA, OmamB, and LucA) could form separate subcomplexes that are recruited to the Mce 




Cryogenic Electron Microscopy 
Cryogenic electron microscopy (cryo-EM) is a method used to determine the 3D shape of 
native proteins or protein complexes (94–98), and could illuminate on transporter size and shape 
when applied to Mce systems. Cryo-EM can be used as an alternative to X-ray crystallography or 
NMR spectroscopy as cryo-EM does not require protein crystallization, which is a process that is 
particularly difficult to achieve for membrane proteins (95, 98). Cryo-EM involves beaming 
electrons at flash-frozen protein samples, which creates images that can be used to reconstruct 
3D shape of native proteins (94, 96, 97). Due to recent technological advances, sub-atomic 
resolution of cryo-EM images has been achieved with the reporting of the structure of the iron-
storing protein, ferritin, at 1.2 Å (99).  
Cryo-EM has been successfully used to characterize the phospholipid transporters of E. 
coli, revealing not only how proteins are assembled but also revealing insight in how such 
organization may promote lipid transport (20–24). Ekiert et al (2017) published a cryo-EM 
structure of the periplasmic domain of the MCE-domain containing protein, MlaD, at 2.85 Å 
resolution. The cryo-EM structure of MlaD revealed that MlaD formed a hexameric pore through 
which phospholipids could potentially travel. Additionally, Ekiert et al (2017) reported on two 
‘constriction’ sites with the C-terminal sequence (~40amino acids) of each MlaD monomer that 
are oriented towards the center of the pore, which Ekiert et al (2017) propose to play a role in the 
passage of small hydrophobic molecules to or from the IM (21). Recently, a 3.05 Å cryo-EM 
structure of the MlaFEDB IM complex has been reported (20). The structure of the MlaFEDB 
complex, has sparked several hypotheses about the mechanism of Mla transport in regards to 
how it may be working in antero- or retrograde transport of phospholipids, as the MlaFEDB 




complex also adds more information about the size and shape of Mla complex than MlaD alone. 
For instance, the stoichiometry of Mla IM complex was determined to be MlaF2E2D6B2. Access 
to the crystal structures of MlaD, MlaF, and MlaB allowed for the designation of specific 
proteins within the cryo-EM structure, which gives further insight into interactions between 
components (20). Cryo-EM structures have also been used to determine the structure of the E. 
coli MCE-domain containing protein YebT/LetB and PqiB (21–23). The cryo-EM structure 
identifies the 7 MCE domains of the YebT/LetB as stacking upon one another, which in 
conjunction with the 6 YebT/LetB monomers forming a homo-hexamer structure, creates an 
enclosed tunnel that could theoretically span between the IM and OM of E. coli (22, 23). While it 
is unknown how MceA-F proteins interact, several different hypotheses can be proposed based 
off of the structures of Mce-domain containing proteins MlaD, YebT/LetB, and PqiB. For 
instance, the six Mce proteins (MceA-F) may form a hetero-hexamer structure at the IM with the 
C-terminal alpha-helices extending through the cell envelope like PqiB (21). It can also be 
speculated that each individual Mce protein forms a homo-hexamer structure like MlaD, and 
then each Mce-domain of the homohexamer stacks with another Mce-domain from a different 
Mce protein like YebT/letB and PqiB, creating a channel that extends within the cell envelope 
(Figure 3.2) (21–23). Thus, there is precedent for using cryo-EM to elucidate the structure of 
multi-protein cell envelope lipid transporter complexes. Application of cryo-EM to Mce 
transporters could be a very powerful approach for revealing how the Mce transporter forms and 
associates in the mycobacterial cell wall.  
 Localization of Mce proteins 
A basic unknown about Mce (MceA-F) proteins is their specific location in the 




function to transport lipids. Depending on their location, Mce proteins (MceA-F) could be 
involved in lipid uptake/transport through the mycobacterial outer membrane (MOM) to the cell 
wall if MceA-F are located at the OM, passage through the cell wall if MceA-F are distributed 
throughout the cell envelope, or across the IM if MceA-F are localized to the IM. Prediction 
programs do not agree on whether Mce proteins contain TM domains or Sec-export signal 
peptides (19); therefore, it is possible that the individual Mce proteins are either tethered at the 
IM via TM domains or are fully exported across the IM and stratified throughout the cell 
envelope. Additionally, the 5th Mce protein of each mce operon, MceE, is almost always a 
predicted lipoprotein, and this conserved distinction suggested the importance of lipid 
modification and subsequent membrane localization (IM or potentially OM). Surprisingly, when 
we tested the significance of the lipoprotein signal by converting the lipoprotein export signal of 
Mce4E to a standard Sec export signal (Mce4EC16A), we found that the lipoprotein export signal 
was not essential to Mce4 function (Chapter 2).  
To study Mce localization, we prepared subcellular factions of M. smegmatis and 
immunoblotted for native Mce4A and Mce4E. We hypothesize that the Mce transporter complex 
consists of MceA-F proteins existing in the cell wall and interacting with an IM complex 
containing the integral membrane permeases, Mam, and Omam proteins. A strong, stable 
association of the cell wall complex (MceA-F) with the IM complex (Yrbs, Mams, and Omams) 
could therefore enable the Mce transporter complex to be pulled into either fraction, which is 
why we detect Mce4A and Mce4E in both the CW and MEM fractions. We had hypothesized if 
Mce4E was an IM lipoprotein, that Mce4E may play a crucial role in facilitating the interactions 
of cell wall Mce proteins (MceA-F) with IM components (YrbE4AB, Mam4AB, OmamAB). 




not shown). Again, we speculate that if protein-protein interactions are very strong within the 
Mce4 transporter, that the other components may have properly localized Mce4EC16A. Overall, 
our attempt to determine the localization of Mce4A and Mce4E proteins did not lead to 
conclusive results or provide insight as to how MceA-F proteins assemble and function in the 
mycobacterial cell envelope.  
Determining important domains and residues of Mce transporter components   
 From bioinformatic analysis, we discovered that the mycobacterial Mce proteins have a 
conserved domain organization. We examined Mce sequences from Mtb and M. smegmatis and 
found common domain composition: 1) an export signal (potential signal peptide or TM domain) 
at the N-terminus, 2) an MCE domain, 3) a Cholesterol_uptake_porter_1 (CUP_1) domain, and 
4) a variable region, which contains no identifiable domains and contains considerable amino 
acid sequence diversity between Mce proteins, at the very C-terminus (Figure 3.3A) (18, 86). We 
also found using phylogenetic analysis that specific Mce proteins across systems (e.g. Mce1A 
and Mce4A) are more similar to one another than the multiple Mce proteins in a given system 
(e.g. Mce4A, Mce4B, Mce4C, etc) (Figure 3.3B) (100). The similarity between MceAs or 
MceBs etc. argues that each MceA-F protein has a unique function, which was confirmed by our 
mutational analysis of Mce4A,E, and F proteins. Based off of the MCE domain present in Mce 
proteins, we speculate that similar to E. coli MCE domain containing proteins, that MceA-F 
proteins form a pore like structure through which lipid substrates can travel. It is currently 
unknown what roles the CUP_1 domain or variable domains play in lipid transport.  
In order to characterize the function of the individual domains of Mce4 proteins, we 
constructed plasmids for expressing mce4A genes encoding proteins missing specific domains 




just the variable domain, Mce4A with only the first 384 amino acids (Mce4A1-384), or lacking 
both the variable and CUP domains, Mce4A with only the first 145 amino acids (Mce4A1-145). 
These Mce4A variants are expressed off of a multicopy plasmid with a strong constitutive 
promoter (hsp60) and contain a C-terminal HA tag. The HA tag was necessary to detect the 
Mce4A variants since our current Mce4A antibody recognizes a peptide sequence in the variable 
domain. Interestingly, when either of these constructs (mce4A1-384-HA or mce4A1-185-HA) were 
transformed into the M. smegmatis Δmce4A mutant, only small, slow and poorly growing 
transformants were recovered. Furthermore, when mce4A1-384-HA or mce4A1-185-HA were 
transformed into WT M. smegmatis, which has a WT copy of mce4A, we observed a similar, 
toxic phenotype as observed in the Δmce4A strain (Figure 3.3C). The toxic effect of Mce4A1-384-
HA or Mce4A1-185-HA is surprising because the Mce4 transporter itself is not essential. 
Presumably, in the WT background the Mce4A1-384-HA or Mce4A1-185-HA constructs caused a 
dominant negative (DN) effect. It is possible that theMce4A1-384-HA and Mce4A1-185-HA, were 
able to incorporate into the Mce4 transporter and that the resulting aberrant transporters change 
the cell wall architecture in such a way that is harmful to the cell. M. smegmatis strains missing 
all six mce operons (Δ6X mce) or only the mce4 operon have an altered colony morphology 
compared to WT when grown on agar containing Congo Red dye, which also suggests that the 
cell wall architecture is affected by Mce4 transporters (50). We further showed that M. 
smegmatis missing a single Mce4 transporter component, such as Mce4A, also presents the same 
colony morphology phenotype (Figure 3.3D). To test this hypothesis of aberrant Mce 
transporters causing a cell wall abnormality and toxic effect, we transformed mce4A1-384-HA and 
mce4A1-185-HA constructs into the M. smegmatis Δ6X mce strain. However, we still observed a 




3.3C). While the toxic effect of our Mce4A domain mutant constructs has so far prevented us 
from studying the significance of conserved MceA-F domains, these constructs could be 
exploited to find suppressor mutations that resolve the toxic effect of our Mce4A domain mutant 
constructs, in order to better understand the interaction between Mce proteins and the cell wall.  
Another finding that denotes the importance of the Variable domain or the C-terminus to 
Mce function was a dominant negative (DN) effect observed when C-terminal epitope tags were 
fused to Mce proteins. As shown in Chapter 2, our Δmce4A and Δmce4E mutants have a growth 
defect on cholesterol and these phenotypes can be reversed to WT levels when WT alleles of 
mce4A or mce4E are expressed from of multicopy or single-copy plasmids. However, when 
Mce4A or Mce4E containing C-terminal epitope tags (either HA or HIS) were produced from 
multicopy plasmids, they only partially complemented the cholesterol growth defects of Δmce4A 
or Δmce4E mutants (Figure 3.3E). Further, WT M. smegmatis producing Mce4A or Mce4E 
containing C-terminal epitope tags expressed from multi-copy plasmids was slightly inhibited for 
growth on cholesterol compared to WT strains expressing empty vector, which suggests a DN 
effect of epitope-tagged Mce4A or Mce4E (Figure 3.3F). We speculate that in the WT 
background the epitope tagged Mce4A and Mce4E are able to incorporate into Mce4 transporters 
and diminish Mce4 function. It is possible that the epitope tagged Mce proteins prevent proper 
and stable complex assembly or substrate binding/transfer. This DN effect of epitope tagged 
Mce4A or Mce4E on WT M. smegmatis was less pronounced when these constructs were 
expressed from single copy plasmids (Figure 3.3E, 3.3F), presumably because fewer epitope-
tagged proteins were available to incorporate into Mce4 transporters. This DN effect caused by 
an epitope tag is much more subtle and specific to Mce4 function than the toxicity effect caused 




mutant domain and epitope tagged Mce4 constructs underscore the importance of the Mce4 C-
terminus to the Mce4 transporter. 
Conserved amino acids of Mce proteins 
Conservation of amino acid residues among Mce proteins may also signify importance to 
function. When scanning the amino acid sequence of mycobacterial Mce proteins, we noticed 
that the majority of Mce proteins contain two conserved cysteine residues in the C-terminal 
Variable domain (Figure 3.4A) (100). Typically, C-terminal cysteines are absent from MceE 
proteins; although, Mce4E contains the single conserved cysteine at its N-terminus at the 
proposed lipoprotein signal peptide cleavage site (19, 100). In addition, for MceD proteins there 
are typically four cysteine residues in the Variable region (100). Cysteines have the potential to 
form disulfide bonds, which could be crucial to forming inter- or intra-molecular bonds (101, 
102). Inter-molecular disulfide bonds might occur between different Mce transporter proteins, 
with a role in complex assembly or stability. Intra-molecular bonds would occur within the same 
protein to allow for proper protein folding. 
To investigate the significance of the conserved cysteines, we constructed a plasmid 
using site directed mutagenesis expressing either mutant mce4AC249S or mce4AC389S, which 
encode for Mce4A with either C-terminal cysteine substituted with a serine. Introduction of a 
plasmid carrying either mce4AC249S or mce4AC389S into the Δmce4A mutant failed to restorethe 
inability of the Δmce4A mutant to grow on or uptake cholesterol, confirming the importance of 
each C-terminal cysteine to Mce4A function (Figure 3.4C-3.4E). Next, we asked if these C-
terminal cysteines of Mce4A were required for interaction with Mce4E by co-
immunoprecipitation using HA-tagged Mce4AC249S or Mce4AC398S. Both Mce4AC249S-HA or 




suggest that the cholesterol growth and uptake defects of Mce4AC249S or Mce4AC398S are not due 
to a defect in interactions with Mce4E specifically or due to destabilization of the larger Mce 
transporter complex. To further support this hypothesis, we next planned to test whether 
expressing mce4AC249S or mce4AC398S in a Δmce4A mutant rescues the defect in Mce4E protein 
levels in the absence of Mce4A. Although the results of our Mce4AC249S-HA or Mce4AC398S-HA 
immunoprecipitations suggest that Mce4E is still stably produced, we experienced difficulty with 
the final experiment. It will be interesting in the future to determine the function of the conserved 
C-terminal cysteines found in many Mce proteins, as well as the functions of other conserved 
residues. 
Conclusions 
Lipids play an important role in the lifestyle of mycobacteria; however, how lipids travel 
through the complex cell envelope of mycobacteria remains a mystery. Mycobacterial Mce 
transporters are lipid importers but their mechanism of transport is largely unknown. Work 
described in this dissertation showed that individual Mce4 transporter components (Mce4A, 
Mce4E, Mce4F, Mam4A, Mam4B, OmamA, and OmamB) are required for Mce4 function. We 
also provided evidence that the YrbE4A,B, Mce4A-F, Mam4AB, OmamA,B, and MceG proteins 
associate in complex to import cholesterol. Much more work though will be needed to determine 
how these proteins assemble to form the Mce4 transporter. Overall structure and assembly of the 
complex remains unknown. Assessing protein-protein interactions within the Mce transporter 
complex is needed for determining how Mce transporter components are connected. 
Additionally, the size, structure, and stoichiometry of individual components in the transporter 
and any subassemblies that are formed prior to complex formation need to be determined. We 




(Mce1 and Mce4), which includes OmamA, OmamB, and LucA, may form a subassembly that 
can move between different Mce transporters. The cryo-EM and crystal structures of E. coli 
MCE-domain containing proteins lead to different models for how mycobacterial Mce proteins 
may exist within the complex. The MceA-F proteins may form a heterohexamer at the IM or 
homo-hexamers that stack on-top of one another (Figure 3.2). In another hypothesis, the CUP_1 
domain of MceA-F, whose secondary structure is largely alpha-helical, will extend up from the 
Mce proteins anchored at the IM through the mycobacterial cell envelope. Further studies will be 
needed to address these possibilities. Our data support that Mce transporters are another example 
of a large, molecular weight complex in the cell envelope that transports substrates across the 
IM. The research presented in this thesis lay the ground work for more detailed biochemical, 
structural, and mechanistic studies that will provide insight into lipid transport, which is a 

















Figure 3.1 Bacterial Adenylate Two Hybrid (BACTH) to identify protein-protein interactions 
among Mce transporter components. 
A. Schematic of BACTH: Adenylate cyclase (AC) is broken into two halves, which include T25 
and T18. Two proteins of interest (protein A and protein B) are fused to the two AC halves (T18 
and T25). Only if proteins A and B interact, will AC activity be restored and downstream genes 
activated (lactose and maltose fermentation operons). Known interactions that are used as 
positive controls for the BACTH assay include Zip-Zip, a leucine zipper protein that strongly 
associates with itself, and MalF-MalG, two E. coli maltose permease subunits of an ABC 
transporter. B. BACTH interactions between full length Mtb OmamA and OmamB proteins as a 
measured by beta-galactosidase activity (Miller Units = OD420nm at time t2–OD420nm at time 
t1)/t2–t1 (min))/OD600nm)). C. BACTH interactions between full length Mtb OmamA and 
OmamB proteins and E. coli MalF as a measured by beta-galactosidase activity (Miller Units). 
D. Periplasmic domains of Mtb OmamA and OmamB as well as M. smegmatis OmamA, 
OmamB, OmamC, and OmamD. “N” indicates N terminus of the protein. The yellow box 
signifies area that was cloned to be the soluble, periplasmic domain with the amino acid residues 
of each soluble, periplasmic domain indicated. E. BACTH interactions between soluble, 
periplasmic domains of Mtb OmamA and OmamB proteins as a measured by beta-galactosidase 
activity (Miller Units) F. BACTH interactions between soluble, periplasmic domains of Mtb 
OmamA and OmamB proteins and E. coli MalF as a measured by beta-galactosidase activity 
(Miller Units). G. BACTH interactions between soluble, periplasmic domains of M. smegmatis 
OmamA and OmamB proteins as a measured by beta-galactosidase activity (Miller Units). H. 
BACTH interactions between soluble, periplasmic domains of M. smegmatis OmamC and 
OmamD proteins as a measured by beta-galactosidase activity (Miller Units). * indicates a 









Figure 3.2 Model of hypothetical Mce4 transporter complex 
A. Hypothetical Mce transporter model with Mce proteins forming a hetero-hexamer, pore-like 
structure. B. Hypothetical Mce transporter model with Mce proteins forming a homo-hexamer, 
pore like structure and stacking upon one another to span the cell envelope, similar to how the 










A. Representation of the four different domains found in Mce proteins: 1) a potential signal 
sequence or transmembrane domain at the N-terminus, 2) an MCE domain identified by PFam 
02470, 3) a Cholesterol_uptake_porter_1 (CUP_1) domain identified by PFam11870, and 4) a 
variable region at the very C-terminus. B. Representation of Mce4A domain mutant constructs 
used in this study in which either the variable domain (Mce4A1-384) or both the variable and 
CUP_1 domains (Mce4A1-145) are missing. C. Toxic and dominant negative effect of Mce4A 
mutant domain constructs described in B. when transformed into Δmce4A, WT, or Δ6X mce M. 
smegmatis strains. D. Morphology phenotype of M. smegmatis strains on Mueller Hinton plates 
supplemented with Congo Red dye. E-J. Growth of 104 colony forming units (cfu) of M. 
smegmatis strains on E, G, I cholesterol or F, H, J glucose and glycerol as the sole carbon(s) 
source was measured over time using resazurin reduction as a fluorescent readout of metabolic 
activity (hν= 544nm excitation and hν= 590nm emission). Mutant strains contain empty vectors 
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Figure 3.4 Conserved cysteines of Mce4A are necessary for Mce4 transporter function but not 
Mce4A-Mce4E interactions 
A. Praline Multiple Sequence Alignment of a segment of Mycobacterium smegmatis MceA 
proteins C-terminus with cysteines highlighted in green. B. Immunoblot confirming expression 
of mce4A complementation plasmids in a Δmce4A strain background. Arrow indicates Mce4A 
band to distinguish it from the higher species cross-reacting band. C. Growth of 104 colony 
forming units (cfu) of M. smegmatis strains on cholesterol as the sole carbon source was 
measured over time using resazurin reduction as a fluorescent readout of metabolic activity (hν= 
544nm excitation and hν= 590nm emission). D. Cholesterol uptake was measured by incubating 
M. smegmatis strains with 4-C14-cholesterol for three hours and the cell associated radioactivity 
was measured using a scintillation counter. Measurements of cholesterol uptake were normalized 
as a percentage of the value of WT M. smegmatis set to 100%. Error bars represent standard 
deviation. * indicates p<0.001 compared to WT. Results are representative of at least three 
independent experiments E. Clarified Whole Cell Lysate generated by passage through a French 
pressure cell was used for co-immunoprecipitation with anti-HA conjugated beads followed by 
immunoblot analysis with HA antibody being used to detect Mce4A-HA constructs and Mce4E 
antibody to detect Mce4E in the co-immunoprecipitate. Strains used for immunoprecipitation 
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APPENDIX I: RESULTS FROM MCE4A-HA IMMUNOPRECIPITATION-MASS 
SPECTROMETRY (IP-MS) 
Table 4.1 LC-MS/MS analysis of immunoprecipitations from strains expressing Mce4A-HA or 
HA only as a control 











Mce4C MSMEG_5898 Rv3497c + 3.025490146 9.63 
Mce4A MSMEG_5900 Rv3499c + 3.057997019 7.83 
Mce4B MSMEG_5899 Rv3498c + 2.740439492 7.17 
Mce4D MSMEG_5897 Rv3496c + 1.512987591 5.40 
Mce4F MSMEG_5895 Rv3494c + 1.782714012 5.02 
MSMEG_0505 
 
+ 2.308095453 4.72 
Mce4E MSMEG_5896 Rv3495c + 1.721811398 4.68 
mimR MSEMG_1970  + 1.523992719 4.68 
MSMEG_5043 Rv1252c + 1.738249516 4.62 
MSMEG_4628 Rv2446c + 2.955997609 4.19 
MSMEG_0267 
 
+ 2.203742072 3.57 
Mce1D MSMEG_0137 Rv0172 + 1.869280496 3.43 
MSMEG_1213 Rv0568 + 3.483352154 3.29 
Mce1E MSMEG_0138 Rv0173 + 1.315573378 3.22 
MSMEG_5850 Rv0775 + 2.036094015 3.00 
MSMEG_6656 
 
+ 1.934343738 2.97 
MSMEG_4735 
 
+ 2.483747279 2.85 
MSMEG_5318 
 
+ 2.127679883 2.84 
Mce1C MSMEG_0136 Rv0171 + 1.512761614 2.81 
YrbE4A MSMEG_5902 Rv3501c + 2.282417486 2.74 
MSMEG_1683 
 
+ 2.807720305 2.48 
MSMEG_1193 
 
+ 2.748487708 2.46 
Mce1F MSMEG_0139 Rv0174 + 1.82565316 2.39 
YrbE4B MSMEG_5901 Rv3500c + 1.983758651 2.35 
MSMEG_2252 
 
+ 2.437235094 2.29 
MSMEG_1217 
 
+ 1.42559026 2.28 
MSMEG_6557 
 
+ 1.684286276 2.28 
MSMEG_3308 
 
+ 1.473920998 2.23 
MSMEG_0771 Rv1865c + 1.341389412 2.20 
MSMEG_1385 
 
+ 1.767100025 2.20 
MSMEG_0418 Rv0248c + 2.818819115 2.19 




MSMEG_0858 Rv0436c + 1.355857351 2.10 
MSMEG_0417 Rv0247c + 2.200553546 2.10 
apt MSMEG_2964 Rv2584c + 1.636610552 2.08 
MSMEG_2188 
 
+ 3.707822569 1.97 
OmamA MSMEG_0235 Rv0199 + 2.764173389 1.96 
MSMEG_5420 
 
+ 2.22777211 1.94 
MSMEG_4339 
 
+ 1.317024554 1.86 
Mam1A MSMEG_0140 Rv0175 + 1.420384675 1.76 
MSMEG_2680 
 
+ 2.19696734 1.74 
MceG MSMEG_1366 Rv0655 + 2.334069396 1.71 
MSMEG_2261 
 
+ 1.8918426 1.67 
nuoL MSEMG_2052 Rv3156 + 2.069977608 1.66 
MSMEG_2260 
 
+ 1.331877404 1.63 
MSMEG_4527 Rv2391 + 1.567211698 1.62 
MSMEG_0330 
 
+ 1.706272595 1.62 
MSMEG_5651 
 
+ 2.328592298 1.61 
MSMEG_0982 
 
+ 1.524061706 1.61 
gap MSMEG_0403  + 2.480800709 1.60 
putP MSMEG_5303  + 1.783800122 1.60 
MSMEG_5317 Rv0314c + 1.672830941 1.55 
MSMEG_3059 Rv1400c + 1.902517314 1.55 
MSMEG_6347 
 
+ 1.424417394 1.48 
OmamB MSMEG_0236 Rv0200 + 2.383246906 1.47 
hybC MSMEG_2263  + 3.343492326 1.47 
lpqB MSMEG_1876 Rv3244c + 1.431796203 1.47 
MSMEG_1901 
 
+ 1.58607389 1.43 
Mam4B MSMEG_5893 Rv3492c + 3.241386385 1.42 
MSMEG_5267 
 
+ 1.354390958 1.41 
MSMEG_3306 
 
+ 1.929844668 1.39 
Mam4A MSMEG_5894 Rv3493c + 2.268654718 1.38 
MSMEG_1177 
 
+ 1.640327876 1.32 
MSMEG_3000 Rv2575 + 1.345729339 1.30 
MSMEG_2610 
 
+ 1.671744626 1.26 
MSMEG_5816 
 
+ 3.215726679 1.25 
MSMEG_4297 
 
+ 2.129619863 1.24 
MSMEG_5304 
 
+ 1.77021118 1.24 
MSMEG_5372 
 
+ 2.078804641 1.23 
glnT MSMEG_6260  + 1.696127681 1.19 
hybA MSMEG_2262  + 1.547741489 1.17 
MSMEG_4078 
 
+ 1.673033224 1.12 
MSMEG_4761 
 
+ 1.868096135 1.11 
MSMEG_2619 Rv2846c + 2.019097985 1.10 
MSMEG_0885 
 




pcaC MSMEG_6370  + 1.67071912 1.08 
MSMEG_4462 
 
+ 1.524399341 1.08 
MSMEG_6213 
 
+ 1.714855179 1.05 
MSMEG_3810 Rv1637c + 1.984682732 1.02 
MSMEG_0688 Rv0337c + 1.628107311 1.01 
MSMEG_4670 
 




























APPENDIX II: RESULTS FROM MCE4E-HA IMMUNOPRECIPITATION_MASS 
SPECTROMETRY (IP-MS) AND COMPARISON WITH RESULTS FROM MCE4A-HA 
IP-MS 
In Chapter 2 of this dissertation, we use immunoprecipitation (IP) combined with mass 
spectrometry (MS) to identify proteins that associate with Mce4A-HA in Mycobacterium 
smegmatis. Using label free quantitation (LFQ) on proteins identified by > two unique peptides, 
we identified proteins with significantly enhanced abundance in the Mce4A-HA IP versus the 
control IP from M. smegmatis expressing HA alone.  Proteins with a p-value <0.05 and a 
minimum 2-fold enrichment (log2 = 1.0) in the Mce4A-HA immunoprecipitation compared to 
control (HA only) were considered interactors 
In parallel, we performed IP-MS on Mce4E-HA IPs. The LFQ data from the Mce4A-HA, 
Mce4E-HA, and HA control IPs was subjected to multiple comparison analysis using analysis of 
variance (ANOVA). Proteins with a q-value <0.05 and a minimum 2-fold enrichment (log2 = 
1.0) in the Mce4A-HA and/or Mce4E-HAs IPs compared to control (HA only) were considered 
interactors. 
 From the IP-MS analyses, we considered it possible that we would identify proteins in 
the following categories: 1) Mce4 transporter proteins that were previously implicated in Mce4 
function, 2) currently unknown components of the Mce4 transporter, or 3) proteins that enable 
assembly of the large, multi-protein Mce4 transporter complex through the cell wall layer. In 
total, 104 proteins were identified as significantly enriched in the Mce4A-HA and/or Mce4E-HA 
IPs compared to the control (Table 5.1). 44 of these 104 proteins have Mtb H37Rv homologs. 43 
of the 44 Mtb homologs have been experimentally identified or are predicted to be exported 
proteins, and their exported localizations supports the hypothesis that they could be components 




Of the 104 proteins identified as enriched in the Mce4A-HA and/or Mce4E-HA IPs 
compared to the control, 43 proteins met our criteria for being interactors in both Mce4A-HA 
and Mce4E-HA immunoprecipitations (Figure 5.1C). Of note all six Mce4 proteins (Mce4A-
Mce4F) were identified as significant and enriched >2 fold in both Mce4A-HA and Mce4E-HA 
IPs (Table 5.1, Figure 5.1C). Additionally, the IP-MS analysis revealed both Mce4A-HA and 
Mce4E-HA to associate with Mce1 proteins (Table 5.1, Figure 5.1). Mce1D and Mce1F were 
identified as interactors in both Mce4A-HA and Mce4E-HA IPs, whereas Mam1B was found as 
an interactor of the Mce4A-HA IP, and Mce1A was identified as an interactor of the Mce4E-HA 
IP (Table 5.1, Figure 5.1). As discussed in Chapter 2, the significance of interactions detected 
between Mce4 and Mce1 systems remains unclear, and will require further study to understand. 
22 of these 43 proteins have Mtb (H37Rv) homologs (Table 5.1). Because these 22 proteins are 
also found in Mtb, which also has a functional Mce4 transporter, these proteins are candidates for 
being additional conserved proteins that function as part of the Mce4 transporter. Two interesting 
proteins in this group are LprE (MSMEG5043/Rv1252c), a predicted lipoprotein, and 
MSMEG4268/Rv2200c, an uncharacterized protein of unknown function. In Mtb, LprE 
promotes Mtb survival in macrophages by suppressing TLR2-dependent cathelicidin bursts and 
by suppressing recruitment of autophagy effectors, as demonstrated by Mtb ΔlprE mutant 
analyses (4). MSMEG4268/Rv2200c, while of unknown function, is of interest for future studies 
because it was among the five most highly enriched proteins identified in both the Mce4A-HA 
and Mce4E-HA IPs compared to the control.  
Of the 104 significantly enriched proteins identified by IP-MS, 33 were identified as 
significant in the Mce4E-HA, but not the Mce4A-HA IP-MS ANOVA analysis (Table 5.1, 




noteworthy, is MSMEG4254/Rv2187, which is a predicted long-chain-fatty-acid CoA ligase that 
is functionally categorized as being involved in lipid metabolism (5). Since Mce transporters 
interact with lipids, it is interesting to think of the possibility that MSMEG4254/Rv2187 
modifies lipids upstream or downstream of Mce4-dependent lipid import. Other interesting 
proteins identified as significantly interacting with the Mce4E-HA IP include MmpL5 and 
Wag31. MmpL proteins are typically involved in transporting lipids across the IM of 
mycobacteria (6, 7). Because Mce transporters and MmpL proteins are both involved in 
mycobacterial cell envelope lipid transport, Mce transporters could potentially coordinate 
function with MmpL transporters to regulate cell envelope biogenesis. For instance, Mce 
transporters may import lipids that could be used as precursors to build substrates for MmpL 
transport across the inner membrane for assembly into the cell envelope.  Alternatively, Mce 
transporters and MmpL proteins could work together to transport lipids into or out of the cell. 
However, so far, MmpL5 has only been shown to function in the transport of siderophores (8) 
and has been suggested to function as an efflux pump of several antibiotics (9), with no known 
role in lipid transport. Wag31 is an essential protein involved in cell division (10). 
Fluoresceinated vancomycin conjugate (Van-Alexa568) will bind to and label the terminal D-
Ala-D-Ala of peptidoglycan precursors (un-crosslinked peptidoglycan), and visualization of 
Van-Alexa568 is used to monitor sites of new peptidoglycan synthesis (10). In mycobacteria 
when Wag31 protein levels are depleted, fluorescent Van-Alexa568 signal was weaker and more 
dispersed whereas fluorescent signal was strongly localized to the cell-poles of WT 
mycobacteria. Fluorescently labeled Wag31 also colocalizes with Van-Alexa568 signal. Wag31 
has therefore been suggested to play either a direct or indirect role in peptidoglycan synthesis at 




an interaction with Wag31 may potentially reflect a role for Wag31 coordinating cell wall 
peptidoglycan synthesis to allow for the construction of large transporters, like Mce systems, 
within the cell envelope and potentially at the cell pole.  
 Twenty-seven of the 104 significantly enriched proteins identified by IP-MS, were 
identified as significant in the Mce4A-HA, but not the Mce4E-HA when using ANOVA 
analysis. Ten of these 27 proteins also have Mtb (H37Rv) homologs. As noted in Chapter 2, all 
the other Mce4 transporter components, including the permeases (YrbE4A, YrbE4B), ATPase 
(MceG), Mam4A,B, and OmamA,B proteins were identified as interactors in the Mce4A-HA IP-
MS analysis, whereas the only Mce4 transporter components identified as interactors of the 
Mce4E-HA were Mce4A-F. Why additional Mce4 transporter components (YrbE4A,B, 
Mam4A,B, OmamA,B, and MceG) were identified as interactors only in the Mce4A-HA IP 
remains to be understood.  One possibility is that Mce4A interacts with or forms subcomplexes 
with an integral membrane complex consisting of the inner membrane transmembrane containing 
components YrbE4A,B, Mam4A,B, and OmamA,B proteins with the cytoplasmic ATPase 
(MceG) further associating with these proteins from the cytoplasmic side of the membrane, 
whereas Mce4E only stably interacts with the other Mce4 proteins (Mce4A-F) and not additional 
components of the system. Alternate possibilities include that the mce4A-HA construct is more 
strongly expressed or that the HA-peptide on Mce4A-HA is more accessible to HA antibody, and 
consequently, the Mce4A-HA IP was more robust in revealing associated proteins. However, the 
raw IP-MS data does not suggest that the Mce4A-HA IP was more robust than the Mce4E-HA 
IP. For example, the Mce4E-HA IP identified more unique interactors than the Mce4A-HA IP 
(33 versus 27 respectively). Additionally, the Mce4E-HA IP interactors were in general 




For the multi-comparison analysis of LFQ differences between Mce4A-HA IP, Mce4E-
HA IP and the HA only control, significant differences were identified by ANOVA (Table 5.1, 
Figure 5.1). The same LFQ data for the 4A-HA IP and HA-only control were analyzed by a 
Student’s t-test to identify significant differences discussed in Chapter 2. In the multi-
comparison analysis using ANOVA, 70 proteins were identified as Mce4A-HA IP interactors 
(Table 5.1, Figure 5.1), whereas 81 proteins were identified as Mce4A-HA IP interactors in the 
single comparison to the HA-only control and Student’s t-test. In comparing the results from 
these different analyses of the data, 54 proteins were identified as significant interactors in both 
of the analyses, including all the Mce4 transporter components (YrbE4A,B, Mce4A-F, 
Mam4A,B, OmamA,B, and MceG). 
Overall, the results from the Mce4A-HA and Mce4E-HA IP analyses demonstrate that 
Mce4A-F proteins strongly associate with one another. Given that the E. coli MCE-domain 
containing proteins MlaD, PqiB, and YebT, form homo-hexameric pore-like structures, we 
hypothesize that MceA-F proteins similarly interact with one another to form stable hetero-
hexamers or homo-hexamers for lipids to travel through. The Mce4A-HA IP analysis identified 
all Mce4 transporter components (with the exception of LucA, which may form a transient 
interaction), including the permeases (YrbE4AB), Mam4A,B, OmamA,B, and ATPase (MceG), 
which supports our hypothesis that these components associate to form a large, multi-protein 
complex within the mycobacterial cell envelope. Other interesting interactors that were identified 
in the IP-MS analyses (LprE, MSMEG4268/Rv2200c, MSMEG4254/Rv2187, MmpL5, and 
Wag31) require further validation of an interaction and characterization to determine if they 





Figure 5.1 Label free quantitation of proteins enriched in the Mce4A-HA and Mce4E-HA 
immunoprecipitations 
A. Proteins identified by > two unique peptides in Mce4E-HA immunoprecipitation as compared 
to an HA only control are shown plotted by log2 (MceE-HA/control) and -log10(p value). 
Proteins with a q-value <0.05 and a minimum 2-fold enrichment (log2 = 1.0) in the Mce4E-HA 
immunoprecipitate compared to control were considered interactors. B. Proteins identified by > 
two unique peptides in Mce4A-HA immunoprecipitation as compared to an HA only control are 
shown plotted by log2 (Mce4A-HA/control) and -log10(p value). Proteins with a q-value <0.05 
and a minimum 2-fold enrichment (log2 = 1.0) in the Mce4A-HA immunoprecipitate compared 




identified in either analysis of the Mce4A-HA immunoprecipitation, Mce4E-HA 





















Table 5.1 Significant interactors of Mce4A-HA, Mce4E-HA, and HA-only control IP-MS 






















Rv3497c mce4C 8.909037 5.652586 0 + 23 
MSMEG_
5900 
Rv3499c mce4A 7.591209 2.814369 0.009185 + 12 
MSMEG_
5899 
Rv3498c mce4B 6.748282 4.287477 0.016364 + 16 
MSMEG_
5897 





5.178435 5.277864 0.010462 + 2 
MSMEG_
5895 
Rv3494c mce4F 4.92083 2.328908 0.03 + 16 
MSMEG_
5896 

















3.538201 3.519805 0.016981 + 3 
MSMEG_
5043 









3.192001 1.061831 0.018175 + 3 
MSMEG_
0137 













2.906145 3.393787 0.008267 + 4 
MSMEG_
5902 




2.664522 1.983205 0.035084 + 3 
MSMEG_
2052 




2.583186 1.747349 0.01181 + 6 
MSMEG_
5901 







kdpD 2.217366 3.14182 0 + 8 
MSMEG_
0771 
Rv1865 yqjQ 2.197235 2.765767 0.043309 + 6 
MSMEG_
0139 


































1.834874 1.853697 0.042443 + 4 
MSMEG_
1366 




1.701512 0.974664 0.023175 + 2 
MSMEG_
0235 
















1.631819 2.333417 0.034248 + 11 
MSMEG_
5893 

















gap 1.56364 0.402407 0.01239 + 3 
MSMEG_
0141 








hybC 1.463416 0.502466 0.030981 + 14 
MSMEG_
0236 












1.370473 1.021528 0.024396 + 4 
MSMEG_
5894 




































































































































0.472055 1.990688 0.035729 + 14 
MSMEG_
0134 
Rv0589 mce1A 0.404109 1.035668 0.035052 + 5 
MSMEG_
5394 
Rv1031 kdpC 0.383271 2.924135 0.043003 + 5 
MSMEG_
1140 


































-0.11521 1.088905 0.028548 + 9 
MSMEG_
5393 















-0.45925 4.326215 0.00775 + 16 
MSMEG_
4217 
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